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1 Abbreviations and Symbols 
AAV Adeno-associated virus Prefixes 
 
AC Adenylyl cyclase k kilo-10
3
 
Ad Adenovirus c centi-10
-2
 
Akt Protein kinase B m milli-10
-3
 
ANP Atrial natriuretic peptide μ micro-10
-6
 
AP Action Potential n nano-10
-9
 
BNP B-type natriuretic peptide p pico-10
-12
 
cAMP Cyclic adenosine monophosphate   
cDNA Complementary DNA 
  
cGMP Cyclic guanosine monophosphate 
  
CMV Cytomegalovirus  
  
DMEM  
Dulbecco's Modified Eagle 
Medium 
  
DNA Deoxyribonucleic acid   
E. coli Escherichia coli   
eGFP 
Enhanced green fluorescent 
protein 
  
ER Endoplasmic reticulum   
ERK 
Extracellular signal regulated 
kinase 
  
FCS Fetal calf serum   
GAPDH 
Glyceraldehyde 3-phosphate 
dehydrogenase 
Symbols  
GPCR G-protein coupled receptor ~ Approximately 
HEK Human embryonic kidney cell °C Degree Celsius 
HF Heart failure ANOVA Analysis of variance 
ISO Isoproterenol Ca
2+
 Calcium 
ITR Inverted terminal repeat CO2 Carbon dioxide 
LB  Luria-Bertani medium ddH2O  Double-distilled water 
LV 
 
Left ventricle EtOH Ethanol 
LVEF Left ventricular ejection fraction g Gram 
MMPs Matrix metalloproteinases h Hour 
mRNA Messenger RNA H2O  Water 
NOS Nitric oxide synthases i.p. Intraperitoneal 
NRACM Neonatal rat atrial cardiomyocytes I.U. International unit 
NRVCM 
Neonatal rat ventricular 
cardiomyocytes 
i.v. Intravenous 
PBS Phosphate buffered saline kb  Kilo bases 
PCR Polymerase chain reaction kDa Kilodalton 
PEI Polyethylenimine L Liter 
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PFA Paraformaldehyde M 
Molar (mol/L); also molar mass 
(g/mol) 
PI3K Phosphoinositide 3-kinase m Meter 
PKA Protein kinase A Max  Maximum 
PKC Protein kinase C Min  Minute 
PLB Phospholamban MOI Multiplicity of infection 
P-PLB(S16) 
Phosphorylated phospholamban at 
serine 16 
mol Mole 
P-PLB(T17) 
Phosphorylated phospholamban at 
threonine 17 
n 
Number of experimental 
replicates 
RLN Relaxin  NaCl Sodium Chloride 
RNA Ribonuclic acid NO Nitric oxide 
RV Right ventricle OD  Optical density 
RXFP1 Relaxin family peptide receptor 1 P/S Penicillin-streptomycin 
RyR2 Ryanodine receptor pH 
Negative decimal logarithm of 
the hydrogen ion concentration 
SERCA2a 
Sarco/endoplasmic reticulum 
Ca
2+
-ATPase 
RPM  Rounds per minute 
SR Sarcoplasmic reticulum s.c. Subcutaneous 
SV40  Simian vacuolating virus 40 V Volt 
TAC Trans-aortic constriction vg Viral genome 
βAR β-adrenergic receptor  Δ Difference 
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2 Summary  
2.1 German 
Trotz des Fortschritts in der modernen Medizin ist die Herzinsuffizienz nach wie vor 
eine der häufigsten Todesursachen in den Industrieländern. Die Herzinsuffizienz ist eine 
fortschreitende Erkrankung, die das Herz allmählich beeinträchtigt. Sie ist allgemeiner 
Endpunkt aller Herzerkrankungen und es gibt derzeit keine ursächliche Behandlung. 
Therapeutische Ansätze zur Behandlung der Herzinsuffizienz konzentrieren sich lediglich 
darauf, das Fortschreiten der Erkrankung zu verlangsamen oder zu verhindern, aber sie zielen 
nicht auf die zugrunde liegenden molekularen Veränderungen im Herzen ab. Daher sind 
neuartige therapeutische Ansätze erforderlich, um die zugrunde liegenden Ursachen der 
Herzinsuffizienz wirksam zu behandeln. Relaxin (RLN) und dessen Rezeptor, RXFP1, haben 
in letzter Zeit aufgrund zahlreicher vorteilhafter Effekte besonders im Zusammenhang mit 
kardiovaskulären Erkrankungen Aufmerksamkeit erregt. Es wurde beobachtet, dass die 
Aktivierung von RXFP1 durch RLN neben vasodilativen, antifibrotischen und 
antiapoptotischen Effekten auch positiv intrope Wirkungen sowohl im insuffizienten als auch 
im gesunden Vorhof-Myokard hat. Interessant ist dabei, dass Vorhöfe und Ventrikel ein 
unterschiedliches RXFP1-Expressionsmuster aufweisen und ventrikuläre Kardiomyozyten 
daher nicht auf eine RLN-Behandlung ansprechen. 
Ziel dieser Arbeit war es daher, die Effekte einer Kombinationstherapie aus ektoper 
ventrikulärer RXFP1-Expression und exogener RLN-Stimulation in einem Herzinsuffizienz-
Modell zu untersuchen. Hierzu wurden Mäuse einer transaortalen Konstriktion (TAC) 
unterzogen, um eine Herzinsuffizienz herbeizuführen. Anschließend wurde bei den Mäusen 
zunächst ein Gentransfer mittels Adeno-assoziierter Viren (AAV) durchgeführt und 
schließlich durch Implantation osmotischer Pumpen eine chronische RLN-Gabe erreicht.  
Durch den AAV-vermittelten Gentransfer wurde eine stabile Überexpression von 
RXFP1 im ventrikulären Myokard erreicht. Nebenwirkungen der viralen Behandlung 
konnten weder in gesunden noch in insuffizienten Tieren beobachtet werden. Die 
Kombination aus RXFP1-Gentherapie und chronischer RLN-Gabe erzielte eine deutliche 
Verbesserung der TAC-induzierten Herzinsuffizienz, während die alleinige RXFP1-
Gentherapie die Tiere zumindest vor der Entwicklung einer schweren Herzinsuffizienz 
schützte. Die Aktivierung von RXFP1 hatte einen signifikanten Einfluss auf die cAMP-
Akkumulation und die Phosphorylierung von Phospholamban (PLB) an Serin-16. Dies führte 
Summary 
 12 
zu einem höheren Ca
2+
-Gehalt im Sarkoplasmatischen Retikulum (SR), was wiederum die 
positive Inotropie bedingt haben könnte. 
Insgesamt konnte in der vorliegenden Arbeit gezeigt werden, dass ein 
gentherapeutischer Ansatz, bestehend aus RXFP1-Überexpression und gleichzeitiger RLN-
Gabe, eine Aktivierung inotroper Signalwege im ventrikulären Myokard induziert, was 
schließlich zu einer deutlichen Verbesserung der Pumpfunktion in einem murinen 
Herzinsuffizienz-Modell geführt hat.  
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2.2 English 
Despite advances in modern medicine, heart failure (HF) is one of the leading causes of 
death in developed countries. HF is a progressive condition that gradually affects the heart. It 
is a common end point for all heart diseases. There is no definite treatment currently 
available. Therapeutic approaches focus on slowing the progress of the disease but do not 
treat the underlining molecular changes in the heart. Therefore, a novel approach is needed to 
effectively treat the underlining molecular causes of HF. Relaxin (RLN) and its cognate 
receptor, RXFP1, have recently gained recognition in the setting of cardiovascular disease 
because of their beneficial vasodilator, anti-fibrotic, anti-apoptotic, and other properties. 
Furthermore, studies have shown that activation of RXFP1 by RLN induces positive 
inotropic effects from both failing and non-failing atrial myocardium. Interestingly, 
ventricular cardiomyocytes do not respond to RLN treatment due to a distinct RXFP1 
expression pattern between atria and ventricles.  
Thus, the aim of this study was to investigate the effects of a combined RXFP1 gene 
transfer with RLN stimulation in the setting of a murine HF model. A trans-aortic 
constriction (TAC) operation was performed on mice to induce HF. Adeno-associated virus 
(AAV) was used for gene transfer followed by chronic RLN administration via osmotic 
pumps. Further investigation of the RXFP1 signaling pathway was also performed in an in 
vitro setting to support the findings from the in vivo model.  
AAV transduction achieved a stable overexpression of RXFP1 in the ventricle. No 
adverse effect from the viral treatment was detected in either healthy or HF animals. RXFP1 
gene therapy with chronic RLN administration was able to rescue TAC induced HF, while 
RXFP1 gene therapy alone only protected the animals from the development of severe HF. 
RXFP1 activation significantly affected cAMP accumulation and phosphorylation of 
phospholamban (PLB) at serine 16 leading to an increase in sarcoplasmic reticulum (SR) 
Ca
2+
 content which might explain the observed positive inotropy. Prolonged RXFP1 
activation did not result in detrimental Ca
2+
 mishandling like other inotropic stimuli. Finally, 
the RXFP1-RLN signaling pathway resembled that of other β-adrenergic signaling pathways 
but with a significant reduction in initial activation strength, which seemed to be pivotal for 
prolonged inotropic effects and favorable molecular changes. 
In conclusion, gene therapy treatment consisting of RXFP1 overexpression and chronic 
RLN administration could rescue HF by artificially inducing inotropic responses in the 
ventricle through ectopic expression of RXFP1 with RLN administration. 
Introduction 
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3 Introduction 
3.1 Heart failure 
3.1.1 Epidemiology and definition of heart failure 
Heart failure (HF) is one of the leading causes of death in developed countries [1]. It 
is responsible for 17 million deaths worldwide and 23 million adults are currently living with 
HF [2]. In Germany, approximately 26,000 new cases of HF are diagnosed annually [3]. 
HF is a chronic progressive condition that affects the pumping power of the heart 
muscles. The condition is defined by a reduced ability of the heart to pump sufficient 
oxygenated blood to meet the body’s requirements [4]. Symptoms attributed to the 
progression of HF include reduced contractility, reduced energy metabolism, chronic 
neuroendocrine activity and increase incidence of both atrial and ventricular arrhythmias [5, 
6].  
 
3.1.2 Causes of HF 
HF is a result of trigger events that damages cardiac muscle and impairs cardiac 
myocytes. This initial trigger event can have a sudden onset (e.g. myocardial infraction) or a 
gradual insidious onset (e.g. volume overloading or hemodynamic pressure) or hereditary [7]. 
Conditions such as hypertension, faulty valve conditions, cardiomyopathy, congenital heart 
defects and coronary artery disease may result in HF if left untreated [8]. Chronic diseases 
such as diabetes, obesity, and sleep apnea may increase the risk of HF [8, 9]. Chronic drug, 
tobacco, and alcohol use also increase the risk of HF at an earlier age [9]. 
 
3.1.3 Different types of HF 
Left ventricular heart failure can be classified into two types which are heart failure 
with reduced ejection fraction (HFrEF), and heart failure with preserved ejection fraction 
(HFpEF). In HFrEF, the left ventricle loses its ability to properly contract. This leads to 
insufficient pumping force to push blood through the circulatory system [10, 11]. To 
compensate for the insufficient output, the left ventricle pumps harder and grows weaker and 
thinner. As a consequence, blood flows backwards into organs leading to fluid buildup in the 
lungs and/or swelling (edema) in other parts of the body [6]. In contrast, HFpEF, occurs 
when the left ventricle becomes stiffened and loses its ability to properly relax. This leads to 
insufficient filling of blood into the LV during the resting period and ultimately results in a 
reduction of blood pumped out to the body [5, 12]. Overtime this causes blood to build up 
Introduction 
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inside the left atrium and lung leading to fluid congestion and classical symptoms of HF [13, 
14].  
 
3.1.4 Molecular alteration leading to heart failure 
Cardiac remodeling, inflammation, and oxidative stress all play a role in altering 
transcriptional regulator networks that could consequently lead to the development of HF [15, 
16]. HF is a progressive disease that gradually develops after the initial triggering event. The 
body will activate compensatory mechanisms to oppose the declined cardiac output [17, 18]. 
One prominent compensatory mechanism is the activation of the sympathetic nervous system 
and stimulation of β-Adrenergic Receptors (β-AR) [19, 20]. These receptors respond to a 
variety of stimuli (e.g. exercise, blood loss, increased sympathetic tone, etc.) to increase 
cardiac output, by altering cardiac rate (chronotropism), cardiac contraction (inotropism) and 
cardiac relaxation (lusitropism). The two types of β-ARs, β1 and β2, are expressed in the heart  
 
 
Figure 1: Prolonged activation of -Adrenergic receptors leads to HF.  
(1) After ligand (A) binds to GPCR, normal cell signaling occurs, (2) After a prolonged  
period of activation, GRKs phosphorylate residues in the carboxyl tail of GPCRs, (3) 
Phosphorylation of carboxyl tail leads to recruitment of -arrestin (ARR), (4) -arrestins 
recruit clathrin and AP-2 complex, (5) GPCRs are targeted for clathrin-mediated endocytosis, 
(6) Endocytosis GPCRs can be recycled or reinserted into the membrane. The figure was 
modified from Pierce et al. [21]. 
Introduction 
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in a ratio of 70%:30% [22, 23]. Both types of receptors are responsible for increased cardiac 
contractility and heart rate [24]. After cardiac remodeling starts to manifest and cardiac 
output declines, the body will increase cardiac output by increasing sympathetic tone leading 
to hyper-activation of β-ARs. Prolonged activation of β-ARs leads to desensitization and 
internalization of the β-receptors by β-arrestins (βARRs), which results in a blunted cardiac 
contractile response to β-adrenergic activation [18, 20] (Figure 1). Accompanying the 
reduction in βARs density is the alteration of β-adrenergic signaling [25]. Moreover, marked 
increase in Gi expression leads to a decrease in Gs:Gi ratio [26]. A down regulation of 
AC V and AC VI has also been reported [27]. These changes in the β-adrenergic signaling 
pathway lead to a decrease in cAMP production, PKA activation and PLB phosphorylation. 
These alterations result in SERCA2a inactivation which decreases cardiac relaxation. Hajjar 
et al. reported that a decrease in SERCA2a expression and activity in HF could impair SR 
Ca
2+
 reuptake and consequently diastolic dysfunction. Altogether these changes in βAR 
signaling pathway and effector proteins gradually blunt and worsen cardiac responses upon 
adrenergic stimulation. As a result, left ventricular function deteriorates, leading to 
subsequent cardiac decompensation, and ultimately symptomatic HF [28].  
 
3.1.5 Current treatments and prognosis 
While mild HF can be treated with lifestyle changes and medications, current 
therapeutic options for treating advanced HF are limited to preventive and supportive 
treatments. Figure 2 shows therapeutic algorithm for patients with symptomatic HFrEF. The 
most common treatment for advanced HF is pharmacological treatment using a combination 
of different medications that target renin-angiotensin-aldosterone and the sympathetic 
nervous system to reduce neuroendocrine activity and increase cardiac output [29, 30]. The 
treatment usually starts with an Angiotensin-converting enzyme inhibitor (ACE-I) and a -
blocker. If still symptomatic, mineralocorticoid receptor (MR) antagonist can be added, and 
ACE-I can be replaced with an angiotensin receptor neprilysin inhibitor (ARNI) [6, 31]. In 
severe cases, implantation of an automatic implantable cardioverter defibrillator (AICD) 
might be indicated to prevent sudden cardiac death, and in terminal HF cases, implantation of 
ventricular assist device or heart transplantation could be indicated [32].  
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Figure 2: Therapeutic algorithm for a patient with symptomatic HFrEF. 
Green indicates recommended treatments and yellow indicates treatments that should be 
considered. ACEI = angiotensin-converting enzyme inhibitor; ARB = angiotensin receptor 
blocker; ARNI = angiotensin receptor neprilysin inhibitor; CRT = cardiac resynchronization 
therapy; H-ISDN = hydralazine and isosorbide dinitrate; ICD = implantable cardioverter 
defibrillator; MR = mineralocorticoid receptor. The figure was modified from Panikowski et 
al. [6]. 
 
These pharmacological and surgical treatments for HF are designed to only correct 
the body’s compensatory mechanisms and pathways to decelerate the progression of the 
disease and increase the lifespan for patients. However, they do not correct the underlying 
molecular causes of HF which are the pathological changes within the cardiomyocytes. A 
recent study also revealed that these treatments do not increase the quality of life for the 
patients because a high rate of re-hospitalization is still observed (up to 20% re-hospitalize 
within 1 month and 50% within 1 year [33]). This frequent hospitalization also leads to a 
heavy financial burden on the healthcare system which will only increase overtime [34]. 
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Therefore, there is a need for novel therapeutic approaches in order to stop, treat, and, reverse 
the progression of HF. For the past two decades, researches and doctors have discovered 
numerous molecular mechanisms that control cardiac function in both the physiological and 
pathophysiological states. These discoveries couple with recent advancement in gene therapy 
techniques could potentially be used to develop a novel gene therapy treatment that can 
correct the underlying molecular causes of HF. 
 
3.2 Relaxin 
3.2.1 Relaxin structure and expression pattern 
 
 
Figure 3: Structure of RLN H2. 
RLN H2 is synthesized as a prorelaxin consisting of 3 chains: A, B, and C. When the peptide 
matures, the C chain is cleaved, and the A and B chains are linked together with disulfide 
bonds.  The binding site of RLN H2 resides on the B chain as depicted. The figure was 
modified from Hossain et al. and Westhuizen et al. [35, 36]. 
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Relaxin (RLN) is a 6 kDa hormone (Figure 3). It was formerly known as a pregnancy 
hormone, secreted during pregnancy to adjust the cardiovascular system and prepare the 
uterus for the process of birth [37-39]. Similar to insulin, RLN is a heterodimeric protein 
consisting of two peptide chains, A-(24 amino acids) and B-(29 amino acids) linked by 2 
disulfide bonds [40, 41].  
The relaxin gene is located on chromosome 9. The encoded protein is synthesized as a 
single chain called prorelaxin [42]. Prorelaxin contains an additional C-chain that connects 
the two active chains, A and B. Upon secretion, the additional C-chain is cleaved and the 
disulfide bonds form, turning the prorelaxin into mature RLN with A- and B-chains 
connected [43]. There are a total of 3 disulfide bonds in a mature RLN. The disulfide bonds 
are located between: 1) Cysteine 10 and 15 of the A and B chains, 2) Cysteine 11 of the A 
and the B chains, and 3) Cysteine 24 of the A chain and Cysteine 23 of the B chain [44]. The 
concentration of RLN is increased in the female reproductive organs during menstruation and 
pregnancy [45]. However, RLN mRNA is also detectable in other organs such as the heart, 
kidneys, brain, lung, liver and blood vessels [37, 46, 47]. In humans, the insulin superfamily 
contains three isoforms of relaxin (RLN H1-H3) [48, 49]. RLN H2 is the only prominent 
form that can be detected within the circulatory system [50]. In mice, there are two isoforms 
which are RLN H1 and RLN H3 [50]. RLN H1 in mice is comparable to RLN H2 in humans. 
Studies on the RLN H2 structure have shown that the active site of RLN H2 most 
likely consists of the mid region of the B chain and the C-terminal region of the A chain [51]. 
Moreover, a comparison study of the structure of RLN H2 in different species revealed a 
remarkable sequence similarity in the mid region of the B chain, where two arginine residues 
are located [52]. Studies have shown that the two arginine residues, along with isoleucine at 
position 20 on the B chain, are important for interaction with RXFP1 [53, 54].   
 
3.2.2 Role of relaxin in the cardiovascular system 
In the cardiovascular system, RLN is an effective regulator of hemodynamics and 
contributes to positive inotropic, positive chronotropic, and lusitropic responses only in the 
atria of the heart [55]. RLN regulates vascular tone by increasing nitric oxide production 
leading to a decrease in systemic pressure [38].   
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Figure 4: Effects of RLN in the cardiovascular system.  
Summary of the RLN effects in the cardiovascular system based on experimental studies 
using a variety of animal models. In the diagram,  and  indicate increase and decrease, 
respectively. Abbreviations: Ang II, angiotensin II; ANP, atrial natriuretic peptide; CF, 
cardiac fibroblast; ET-1, endothelin-1; NO, nitric oxide [56].  
 
RLN exerts its cardioprotective effects during myocardia injury by preventing 
fibroblast differentiation into myofibroblast and decreasing myocytes apoptosis after cardiac 
damage [57]. The study done by Debrah et al. also revealed that RLN can induce favorable 
hemodynamic changes (i.e. it reduced afterload and increased cardiac index) in an 
experimental hypertensive HF model [58]. Figure 4 summarizes the effects of RLN in the 
cardiovascular system. Boccalini et al. showed that RLN also has anti-ischemic and anti-
inflammatory effects and could stimulate angiogenesis in ischemia reperfusion models by 
upregulation of VEGF to protect the heart from ischemia and reperfusion injury [59]. One 
study also showed that RLN could promote maturation of neonatal-cardiomyocytes in mouse 
[60]. Finally, RLN also produces strong positive inotropic effects in the atrial myocardium 
from both failing and non-failing heart by affecting PKA activation, transient potassium 
current, and calcium accumulation within the sarcoplasmic reticulum [61, 62].  
 
3.2.3 Secretion of relaxin during decompensated HF 
In 2001, Dschietzig et al. reported that the plasma levels of RLN in HF patients 
correlated to the severity of the disease, especially during the decompensation period [46] 
(Figure 5). Several follow up studies with larger cohorts also confirmed the elevated levels of 
RLN during the decompensation period but could not find a correlation between RLN 
concentration and the severity of HF [63-65]. Additional studies identified RLN as a 
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compensatory mediator of HF [46, 64]. During the decompensation period, the heart 
upregulates the RLN gene to produce and release RLN into the circulatory system; as a 
consequent, systemic concentration of RLN increases during decompensated HF, and might 
lead to an increase in cardiac output and a decrease systemic vascular resistant [46, 64].  
 
 
Figure 5: Secretion of RLN during decompensated HF.  
RLN plasma levels increase depending on the severity of HF decompensations. Severe 
decompensation leads to high increase in RLN plasma levels. Figure adapted and modified 
from Dschietzig et al. and Allen et al. [46, 66]. 
 
In summary, RLN is physiologically secreted during pregnancy, but it is widely 
believed that it is also secreted during the decompensation period of HF [46]. Clear evidences 
for the effects of RLN secreted during decompensated HF is still missing, but it is considered 
to be beneficial [49]. As such, there is a great interest in using RLN as a medication specific 
to the treatment of decompensated HF.   
 
3.3 Relaxin Receptor (RXFP1) 
3.3.1 Relaxin receptor structure and expression pattern 
The receptor for RLN is found in different tissues throughout the body. RNA and 
protein expression of RXFP1 could be detected in organs such as the brain, lung, kidneys, 
reproductive tissues, liver, adrenal gland, and atria of the heart. RLN exerts its physiological 
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effects by primarily binding to its cognate receptor RXFP1 previously known as LGR7 [67, 
68]. The receptor contains an N-terminal low-density lipoprotein receptor class A (LDLa) 
module, and it is the only GPCR that contains such a domain [69]. The LDLa module on 
RXFP1 is crucial for receptor activation through ligand-stimulated cAMP signaling. 
Additionally, the receptor also contains a large ectodomain with 10 leucine-rich repeats 
(LRRs) that is important for high affinity ligand binding [54, 70]. This primary ligand 
binding between RLN and RXFP1 is mediated through the interaction of Arg
13
, Arg
17
, Ile
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residues on the RLN B-chain α-helix and several pockets of surface-exposed amino acids 
located in LRR 4–8 on RXFP1 [71]. Like many GPCRs, RXFP1 also contains 7 
transmembrane regions which form loops that embed the receptor into the plasma membrane 
[72, 73]. The extracellular parts of loop 1, 2, and 3 are important for the interaction between 
the receptor and the A-chain of RLN [74]. The C-terminal of the receptor resides within the 
membrane [75]. Figure 6 describes different structural features of RXFP1 in detail.  
 
 
Figure 6: Structural features of the RXFP1.  
RXFP1 has a large extracellular domain that contains a low-density lipoprotein receptor 
type A (LDLa) module connected to a leucine-rich repeat (LRR) region linked to the 
transmembrane domains of the receptor. The primary high affinity binding site for RLN is 
located in the LRR region, but the peptide also interacts with a lower affinity binding site 
located on the extracellular loops [37]. 
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3.3.2 Relaxin receptor signaling pathway in cardiomyocytes 
RLN and its receptor exert various effects through several pathways, especially in 
vascular, renal, and reproductive organs. In this work, the focus will be on RLN effects on 
the cardiovascular system. 
In RXFP1 expressing cell lines, activation of RXFP1 leads to a biphasic cAMP 
response. Figure 7 describes the different pathways involved in RXFP1 signaling by RLN. At 
nanomolar levels of RLN, RXFP1 activates three distinct Gα proteins – Gαs, GαoB, and Gαi3. 
Activation of Gαs leads to an initial increase of cAMP, which is restricted by GαoB and late 
maintained by Gαi3 [47, 76, 77]. To maintain the high amount of cAMP needed, the second 
surge of cAMP comes from the activation of PI3K through Gαi3 and Gβγ [78, 79]. In healthy 
cardiomyocytes, RLN would preferably signal primarily through Gαs, since only a small 
amount of Gαi3 is expressed leading to a limited inotropic response [26].  During HF Gαi3 is 
upregulated in cardiomyocytes while Gαs stays unchanged. Thus RLN could potentially 
utilizes both Gαs and Gαi3 for downstream signaling [26], which could significantly increase 
cAMP production resulting in a positive inotropic response. 
 
 
Figure 7: RXFP1 signaling pathway previously described.  
RXFP1 activation by RLN induces signaling transduction through both Gαs and Gαi3 subunits 
of the heterotrimeric G protein. Activation of the receptor classically increases cAMP 
production and PKA activity resulting in changes in genes expression profile and protein 
phosphorylation states [80].  
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The positive inotropy of RLN was initially described in isolated atrial cardiomyocytes 
of rats. This was later confirmed in atrial cardiomyocytes from failing human hearts [55, 77]. 
In contrast to atrial cardiomyocytes, ventricular cardiomyocytes isolated from the same 
human hearts did not respond to RLN treatment, which could be reasonably explained by the 
distinct RXFP1 expression pattern between the atria and the ventricle [81]. In both rats and 
humans, RXFP1 mRNA and protein are predominantly expressed in the atria while a minimal 
of RXFP1 mRNA is detected in the ventricle. Thus, it might be possible to produce inotropic 
responses in the ventricle, if gene therapy could be utilized to ectopically express RXFP1.  
 In summary, RXFP1 is a G-protein coupled receptor. In cardiovascular system, it is 
highly expressed in the atria of the heart. Upon activation, it preferably couples to Gαs and 
Gαi3 sub-units of the heterotrimeric G-protein to increase cAMP production and PKA 
activation leading to positive inotropy. 
 
3.3.3 Positive inotropic potential from activation of RXFP1 in HF 
A hallmark of -AR activation is an increase in cAMP production [82]. Increased 
cAMP leads to activation of PKA and Epac resulting in phosphorylation of PLB at both 
serine 16 and threonine 17 which activates SERCA2a [83-85]. Activation of SERCA2a 
influences intracellular calcium handling by increasing the rate of calcium being transported 
back into the SR, which contributes to positive inotropic effects [86]. Nonetheless, the 
positive inotropic effects from -AR is only short lived and a prolonged -AR stimulation 
leads to desensitization of the receptor. In HF, global desensitization of -AR by -arrestins 
occurs, leading to a lack of response to  agonists and rendering HF patients irresponsive to 
inotropic stimuli [87]. Modern treatment for HF focuses on preventing desensitization of -
AR using -blockers in order to preserve sufficient cardiac functions. Similar to -AR 
activation, RXFP1 activation by RLN also induces positive inotropy by increasing cAMP 
production and phosphorylation of its downstream target such as PLB [88]. However, there 
are two major differences between the two receptors: 1) RXFP1 is barely desensitized, which 
leads to a prolonged increase in cAMP, and 2) RXFP1 is shown to retain its function in the 
failing heart [55, 89]. This suggests that -AR and RXFP1 are independent receptors that 
work through similar pathways [61, 62]. They might share some parts of the intracellular 
pathway such as cAMP production and PKA activation, but in the presence of desensitized -
AR, the signal from RXFP1 will dominate the overall downstream signal produced since 
minimal signal can go through a desensitized -AR pathway. Thus, when -AR is 
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desensitized in HF, RXFP1 and RLN could potentially be used to induce positive inotropic 
effects to increase cardiac output. 
 
3.3.4 Beneficial effects of ectopic expression of RXFP1 
It has been shown that RXFP1 retains its function regardless of the heart conditions 
[55]. Utilizing gene therapy technology, RXFP1 could be ectopically expressed in the 
ventricle upon HF. RXFP1 gene with cardiac specific promoter could be packed into a single 
strand AAV recombinant vectors to infect the ventricular cardiomyocytes. After infection, the 
beneficial effects of RXFP1 could be harnessed by a controlled administration of RLN. This 
treatment would create a new inducible inotropic pathway in a failing ventricle apart from the 
desensitized -AR. Thus, the method could lead to a new mean of stimulating failing 
cardiomyocytes for positive inotropy.  
 
3.4 Viral assisted human gene transfer 
3.4.1 Definition of human gene transfer 
The concept of human gene transfer (or gene therapy) is defined as the transfer of 
foreign genetic material (DNA or RNA) into a cell, tissue, or organ in order to treat a disease 
caused by defective genes. Human gene transfer according to the definition of the European 
Medicines Agency (EMA) includes any products that use foreign genetic material to add, 
delete, replace, repair, or regulate genetic sequences, which use results in the correction, 
restoration, or modification of the physiological function of humans.  
 
3.4.2 AAV serotypes 
AAV was discovered as a contaminant of an Adeno production in 1965 [90, 91]. A 
hallmark character of an AAV is its inability to replicate in the absence of a co-infecting 
virus. Potential helper viruses include: adenovirus, herpes simplex virus type 1 and 2, 
vaccinia virus, human Papilloma virus type 16, and human cytomegalovirus [92-95]. 
At present, several serotypes of AAV have been discovered. They are characterized 
by distinct variations of antigenic properties. There are 12 different serotypes of AAVs 
identified as AAV1 to AAV12. Serotypes 2, 3, 5, 6, and 9 were isolated from humans [96-
100]. Serotypes 1, 4, 7, 8, 10, 11, 12 were isolated from primates [101-105]. Table 1 shows 
the targeted tissues of different AVV serotypes and their expression levels. All AAV 
serotypes are capable of infecting human cultured cells regardless of their in vivo tropism. 
Introduction 
 26 
Interest in the field of gene therapy led to extensive studies on several different AAV 
serotypes. Due to its remarkable ability to cross the blood brain barrier (BBB), and its strong 
transduction efficiency, AAV9 has recently gained interest in gene therapy studies [106]. In 
cardiac research, AAV9 is the vector of choice due to its strong in vivo cardiac transduction 
in mice. 
Serotypes 
Isolated 
from 
Primary 
tropism 
Expression 
level 
Description 
AAV1 Primate Muscle Medium 
Best for cardiac and 
skeletal muscle 
AAV2 Human 
Muscle, Liver, 
retina 
Low 
Best for neurons, 
muscle, and brain 
AAV3 Human Megakaryocytes Low 
Best for 
megakaryocytes, 
muscle, liver, lung and 
retina 
AAV4 Primate Retina Low 
Best for neurons, 
muscle, brain and 
retina 
AAV5 Human Lung Medium 
Best for lung, neurons, 
synovial joint, retina, 
and pancreas 
AAV6 Human Muscle, Lung Medium 
Best for lung, liver, and 
heart 
AAV7 Primate 
Muscle, retina, 
neurons 
High 
Best for muscle, 
neurons, and liver 
AAV8 Primate Liver High 
Best for muscle, brain, 
liver, and retina 
AAV9 Human Various High 
Best for muscle, heart, 
liver, lung, and brain 
AAV10 Primate Pleura, CNS Medium 
Best for lung, muscle, 
heart, CNS, and liver 
AAV11 Primate Various Low 
Unknown, likely 
similar to AAV4 
AAV12 Primate Various Low 
Unknown, likely 
similar to AAV4 
 
Table 1: AAV serotypes with tropology and expression level [107] 
 
Out of the 12 serotypes, AAV1, 6, 8, and 9 have shown cardiac tropism [108]. 
Recombinant AAVs used for gene therapy are non-pathogenic, have low genome integration 
ratio and offer a long-term transgene expression in non-dividing cells after a single delivery; 
therefore making them generally very safe [109, 110]. Moreover, the small size of AAV 
allows it to be delivered to the myocardium by both direct and systemic injection [110]. 
Introduction 
 27 
However, there are three serious drawbacks of using AAV in gene therapy: 1) the limited 
packaging capacity of ~ 4.7 kbp for a single strain virus and ~ 2.3 kbp for a double strain 
virus, 2) the widely spread neutralizing antibodies against the AVV serotype in humans, and 
3) the inevitable production of neutralizing antibodies upon single or repeated treatments 
with the same serotype, thereby limiting the number of viral treatments a single individual 
can receive [109, 111]. Scientists are currently working to overcome these setbacks by 
creating AAV vectors capable of coinfection and by generating a chimeric AAV vector that 
is not recognized by the immune system [112, 113].  
AAV capsid is build up from 60 subunits of capsid proteins VP1, VP2, and VP3 that 
form an icosahedral viral particle with a diameter of ~ 25 nm [114]. The capsid proteins exist 
in the ratio of 1:1:10 (VP1:VP2:VP3) with 5 copies of VP1 and 2, and 50 copies of VP3 per 
particle (22) [115]. Twenty triangular faces were arranged from trimmers of all three capsid 
proteins. 
 
3.4.3 AAV gene transfer 
Delivery of AAV vectors in mice can be done through intravenous injection, but for 
larger animals such as pig or human, a cardiac specific delivery is required because of it 
minimally invasive nature [116]. In the first human clinical trial of gene therapy in the setting 
of HF (CUPID Trial), an antegrade intracoronary injection was employed [117]. 
After entering the body, AAV vectors gain entry into the cells using different cellular 
receptors such as heparan sulfate proteoglycan, N-linked sialic acid, O-linked sialic acid, and 
O-linked galactose [103, 118, 119]. Internalization is enhanced by interactions with one or 
more of at least 6 known coreceptors including αVβ5 integrins, fibroblast growth factor 
receptor 1 hepatocyte growth factor receptor, αvβ1integrin, and laminin receptor [118, 119]. 
AAVs are able to utilize several pathways such as clatherin-mediated, RacI-mediated or 
CLIC/GEEC mediated for cellular uptake [120-122]. After endocytosis AAV virions are 
trafficked in vesicles along the cellular cytoskeleton [121]. Low pH inside the endocytic 
vesicles triggers a conformational change in the capsid VP1 protein and facilitates its release 
from the endosomes [123]. Next AAVs enter the nucleus through the nuclear pore complex 
or other alternative pathways [121, 124, 125]. Then without the helper virus or the Rep 
protein the viral genomes cannot replicate and persist in the nucleus extrachromosomally as 
episomes [126]. Ribosomes can bind to the episomes to transcript mRNA for protein 
production. Figure 8 shows the process of AAV particles infecting in the cell.  
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Figure 8: Gene Therapy using AAV vectors.  
The diagram depicts gene delivery to a cell by an AAV vector. First, the gene of interest is 
cloned into a recombinant AAV genome and packed into an AAV capsid. The AAV particle 
binds to the cell membrane through several specific receptors and enters the cells cytoplasm. 
After entering the cell, the virus traffics to the nucleus, where the transgene is delivered. The 
transgene remains as an episome and IS transcribed into mRNA. The mRNA is modified and 
transported to the cytoplasm before being translated into protein. The newly formed protein 
can be modified or transported to different compartments within the cell depending on the 
function of the protein [127]. 
 
3.4.4 AAV for cardiac gene therapy 
Collectively AAVs display a very broad tropism, but none of the currently available 
AAVs has shown tropism exclusive in one tissue [116]. Although AAV serotype 1, 6, 8 and 9 
are the more promising serotypes for cardiac gene transfer [107], high specificity is still 
required for a targeted cardiac gene transfer. To further increase cardiac specificity, different 
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cardiac specific promoters can be added to further control the expression of the gene of 
interest [128].  Ventricular specific promoters such as Troponin T (TnT), myosin light chain-
2v (MLC-2v), and α-myosin heavy chain (α-MHC) were previously used in numerous studies 
to achieve high cardiac specificity expression need for gene therapy [128-131]. 
In summary, a combination of a cardiac specific promoter and a targeted HF gene 
construct packing into a recombinant AAV vector can be used to correct molecular changes 
in cardiomyocytes to treat HF from within the cells. This treatment is different from 
conventional treatments because it addresses the underlying molecular changes of HF rather 
than treating the body’s compensation mechanisms which are the result of the molecular 
changes. In the past decades many HF gene therapy targeted proteins have been identified 
and tested for their effectiveness at correcting the underlying molecular changes of HF in a 
gene therapy setting. Several proteins including the one from this study have emerged as 
potential candidate for further testing. 
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3.5 Aims of the study 
Traditionally, RLN and its receptor RXFP1 have been associated with the reproductive 
system. Their role in preparing the cardiovascular system and renal system during pregnancy 
is well established. Interestingly, recent evidence suggests that RLN and RXFP1 might also 
play a much more complex role in the cardiovascular system in HF patients, as elevated 
levels of RLN were detected in decompensated HF patients. However, clinical trials using 
recombinant RLN to treat acute heart failure (AHF), exploiting its vasodilatory properties, 
failed to improve mortality [132]. Expression of RXFP1 has been detected in the atria of HF 
patients and is known to induce positive inotropy under RLN stimulation. As expression of 
RXFPI in the ventricular cardiomyocytes is negligible, no positive inotropy was detected in 
ventricular cardiomyocytes upon RLN stimulation. It is unknown if ectopic RXFPI 
expression alone or in combination with exogenous RLN delivery can induce positive 
inotropy in failing hearts.  
Gene therapy could help combine the benefit of RLN and RXFP1 interaction by 
mediating RXFP1 expression.  
 
As such the hypothesis of this thesis is: 
 
Cardiac gene therapy with AAV-mediated expression of RXFPI alone or in 
combination with exogenous RLN treatment improves cardiac function in murine HF. 
 
Therefore, the aims of this thesis are: 
1) To explore the possibility of ectopically overexpressing a functional RXFP1 in the 
left ventricle using AAV vectors. 
2) To translate RXFP1 overexpression into a treatment for HF in an animal model. 
3) To dissect the molecular signaling pathway of RXFP1 and RLN in left ventricular 
cardiomyocytes. 
4) To differentiate RXFP1 and -adrenergic signaling pathways. 
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4 Materials and Methods 
4.1 Organisms and animals 
4.1.1 Bacteria 
E. coli DH5 
F– Φ80lacZΔM15 Δ(lacZYA-argF) U169 recA1 endA1 hsdR17 (rK–, mK+) phoA 
supE44 λ– thi-1 gyrA96 relA1  
E. coli Top10 
F- mcrA Δ(mrr-hsdRMS-mcrBC) φ80lacZΔM15 ΔlacX74 nupG recA1 araD139 
Δ(ara-leu)7697 galE15 galK16 rpsL(Str
R
) endA1 λ
- 
 
E. coli SURE2 
endA1 glnV44 thi-1 gyrA96 relA1 lac recB recJ sbcC umuC::Tn5 uvrC e14- 
Δ(mcrCB-hsdSMR- mrr)171 F'[ proAB
+ 
lacI
q 
lacZΔM15 Tn10 Amy Cm
R
]  
 
4.1.2 Eukaryotic cell line 
HEK 293T STR Profil: Amelogenin: X 
  CSF1PO: 11,12 
  D13S317: 12,14 
  D16S539: 9,13 
  D5S818: 8,9 
  D7S820: 11,12 
  THO1: 7,9.3 
  TPOX: 11 
  vWA: 16,19 
 
4.1.3 Animals 
In vivo TAC RXFP1 gene therapy model: C57/Bl6NRj (Janvier Labs) 
Neonatal rat ventricular cardiomyocytes isolation: Wistar (Janvier Labs) 
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4.2 Chemicals and reagents 
Denotation Source 
2-Mercaptoethanol Sigma Aldrich, Munich, Germany 
Acetic Acid VWR, Darmstadt, Germany 
Aqua ad injectabilia B. Braun, Melsungen, Germany 
Agarose Sigma Aldrich, Munich, Germany 
Ampicilin Carl-Roth, Karlsruhe, Germany  
Bacteriological Agar BD, Franklin Lakes, USA 
Bacto Trypton -pancreatic digest of Casein  BD, Franklin Lakes, USA 
Bromophenol Blue  Sigma Aldrich, Munich, Germany 
BSA  Sigma Aldrich, Munich, Germany 
Chloroform  Sigma Aldrich, Munich, Germany 
Collagen Type I rat tail Merck, Darmstadt, Germany 
Collagenase Type 2 Worthington, Lakewood, USA 
DEPC H2O  Carl-Roth, Karlsruhe, Germany  
Disodium hydrogen phosphate-2-hydrate Gr ssing GmbH Analytic, Filsum, Germany 
DTT Sigma Aldrich, Munich, Germany 
EDTA AppliChem GmbH, Darmstadt, Germany 
Ethanol 99%   Sigma Aldrich, Munich, Germany 
Ethidiumbromide Carl-Roth, Karlsruhe, Germany  
Fetal Calf Serum (FCS)  GE healthcare, Chicago, USA 
Formaldehyd (37 %)  Sigma Aldrich, Munich, Germany 
Gallein Santa Cruz Biotechnology, Heidelberg, 
Germany 
Glycerin Carl-Roth, Karlsruhe, Germany  
Glycin  AppliChem GmbH, Darmstadt, Germany 
H89 Tocris, Wiesbaden, Germany 
HEPES Carl-Roth, Karlsruhe, Germany  
Hydrochloric acid VWR, Darmstadt, Germany 
iBlock Reagent (Tropix I-Block) AppliedBiosystems, Carlsbad, USA  
iQ SYBR Green Supermix Bio-Rad, Munich, Germany  
iScript cDNA Synthesis Kit Bio-Rad, Munich, Germany  
Isopropanol  AppliChem GmbH, Darmstadt, Germany 
Isoproterenol hydrochloride Sigma Aldrich, Munich, Germany 
Kanamycin Carl-Roth, Karlsruhe, Germany  
KN92 Tocris, Wiesbaden, Germany 
KN93 Tocris, Wiesbaden, Germany 
Laminin  Sigma Aldrich, Munich, Germany 
Magnesium sulfate-7-hydrate Merck, Darmstadt, Germany 
Melittin Tocris, Wiesbaden, Germany 
Methanol Sigma Aldrich, Munich, Germany 
NP40 (Nonidet P40)  Sigma Aldrich, Munich, Germany 
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Optiprep GE healthcare, Chicago, USA 
Pancreatin  Sigma Aldrich, Munich, Germany 
Percoll GE healthcare, Chicago, USA 
Pertussis toxin Tocris, Wiesbaden, Germany 
Phosphatase Inhibitor Cocktail 2,3  Sigma Aldrich, Munich, Germany 
Polyacryl-Carrier  Molecular Research Center, USA  
Potassium chloride AppliChem GmbH, Darmstadt, Germany 
Potassium dihydrogen phosphate Merck, Darmstadt, Germany 
Propranolol hydrochloride Sigma Aldrich, Munich, Germany 
Proteaseinhibitor Complete Mini EDTA- free  Roche, Mannheim, Germany 
Proteinase K AppliChem GmbH, Darmstadt, Germany 
Recombinant Relaxin H2 R&D Systems, Minneapolis, USA 
SDS in Pellets  SERVA GmbH, Heidelberg, Germany 
Sodium Acetate Sigma Aldrich, Munich, Germany 
Sodium chloride Carl-Roth, Karlsruhe, Germany  
Sodium chloride 0,9% intravenous B. Braun, Melsungen, Germany 
Sodium hydroxide Sigma Aldrich, Munich, Germany 
SQ22536 Tocris, Wiesbaden, Germany 
Stauroporine Tocris, Wiesbaden, Germany 
Taurin Carl-Roth, Karlsruhe, Germany  
Tris  Carl-Roth, Karlsruhe, Germany  
Triton X100  Sigma Aldrich, Munich, Germany 
Trizol®  Invitrogen, Karlsruhe, Germany 
Tryptone BD, Franklin Lakes, USA 
Tween 20  Carl-Roth, Karlsruhe, Germany  
Vectashield® Hard Mounting Medium/Dapi  Linaris Biologische Produkte 
Wortmannin Sigma Aldrich, Munich, Germany 
Yeast Extract Carl-Roth, Karlsruhe, Germany  
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4.3 Buffers and solutions 
4.3.1 Solution for molecular biology 
Denotation Composition Source 
6x Agarose Gel loading buffer 
30 % Glycerol (v/v), 0.25 % 
Bromophenol Blue (w/v), 0.05 % SDS 
(w/v) 
Prepare in the lab 
RIPA lysis buffer 
150 mM NaCl, 50 mM Tris, 50 mM 
EDTA, 1 % NP40 (v/v), 0.5 % 
Desoxychola, 10 mM NaF, 10 mM 
Na2-Pyrophosphate, phosphatase 
inhibitor 2 and 3, 1 tablet protease 
inhibitor in 10ml 
Prepare in the lab 
i-Block blocking buffer 
10% 10x TBS, 0.2% i-Block (w/v), 
0.1% Tween 20 (v/v) 
Prepare in the lab 
Semi-Dry transfer buffer 
48 mM Tris, 39 mM Glycin, 20 % 
Methanol (v/v) 
Prepare in the lab 
10x TBS  
0.25 M Tris, 1.5 M NaCl, 10 mM 
CaCl2, pH 7.5 fill up to 2.5 L with 
ddH2O 
Prepare in the lab 
10x Anode buffer 1 M Tris, fill up to 1 L with ddH2O Prepare in the lab 
1x Cathode buffer 
0.1 M Taurin, 0.1 M Tris, 0.1% SDS, 
fill up to 2.5 L with ddH2O 
Prepare in the lab 
10x TAE 
400 mM Tris (pH 7.6), 200 mM acetic 
acid, 10 mM EDTA 
Prepare in the lab 
1x TBS-T 
20 % 10x TBS (v/v), fill up to 0.5 L 
with ddH2O, 0.1 % Tween 20 (v/v) 
Prepare in the lab 
5x SDS-PAGE loading buffer 
30 % Glycerol (v/v), 50 mM TRIS, 10 
% SDS (v/v), 250 mM DTT, 10 mM 
EDTA, 0.1 % Bromophenol Blue 
(w/v), pH 6.8; fill up to 1 L with 
ddH2O 
Prepare in the lab 
4 % Paraformaldehyd  
4 % PFA (w/v), 4 % Sacharose, 1x 
PBS, heat to 60° C, pH 7-8 
Prepare in the lab 
0.5M EDTA (pH 8.0)  
 
Prepare in the lab 
1M Tris-HCl (pH 7.4) 
 
Prepare in the lab 
3M SodiumAcetate (pH 6.2)  
 
Prepare in the lab 
1% SDS lysis buffer 
PBS, 1 mM EDTA, 1 mM EGTA, 1% 
SDS, 1% phosphatase inhibitor 2 and 
3, 1 tablet protease inhibitor in 10ml 
Prepare in the lab 
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4.3.2 Solution for microbiology 
Denotation Composition Source 
10x LB Medium 1L [Bertani, 
1951]  
100 g Bacto trypton, 50 g yeast 
extract, 50 g NaCl, pH 7.2 (adjusted 
with 2M NaOH) 
Prepare in the lab 
LB Medium 1L [Bertani, 
1951]  
10 g Bacto trypton, 5 g yeast extract, 5 
g NaCl, pH 7.2 (adjusted with 2M 
NaOH), for solid nutrient media 20 
g/L of agar was added before 
autoclaving 
Prepare in the lab 
Cyro preservation medium 57.5 ml 87 % Glycerol in H2O, 42.5 
ml TY medium 
Prepare in the lab 
TSS Medium (100 ml) [Chung 
et al., 1989]  
82,5 ml LB0 (pH 6.5), 10 g PEG 6000, 
5 ml DMSO, 2.5 ml 2 M MgCl2 mixed 
before autoclaving 
Prepare in the lab 
TY Medium (500 ml)  5 g Bacto trypton, 2,5 g yeast extract, 
pH 7.2 (adjusted with 2M NaOH) 
Prepare in the lab 
 
4.3.3 Solutions for cell culture 
Denotation Source 
0.25% Trypsin-EDTA (1x)  Gibco (Thermo Fisher Scientific), Waltham, USA  
DMEM with High Glucose Sigma Aldrich, Munich, Germany 
FCS Superior Biochrom, Berlin, Germany 
HBSS  Gibco (Thermo Fisher Scientific), Waltham, USA  
HEPES Buffer Solution 1(M) Gibco (Thermo Fisher Scientific), Waltham, USA  
L-Glutamin 200mM 100x  Gibco (Thermo Fisher Scientific), Waltham, USA  
Medium 199, HEPES Modification  Sigma Aldrich, Munich, Germany 
PBS Sigma Aldrich, Munich, Germany 
Penicillin/Streptomycin (5000U/ml)  Gibco (Thermo Fisher Scientific), Waltham, USA  
Percoll GE Healthcare, Freiburg, Germany 
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4.3.4 Media for cell culture 
Denotation Composition 
Collagenase digestion 
solution 
80 U/mL collagenase type 2, 0.06 % pancreatin (w/v) dissolved 
in 120 mL Aqua ad injectabilia for 45 minutes with maximum 
stirring, 20 mL 10x ADS, and fill up to 200 ml with Aqua ad 
injectabilia, filtered sterile 
Digestion stop solution 25% FCS-Gold by adding 10 mL to 30 mL of digested solution 
Culture medium 
NRVCMs (10 % FCS)  
Medium 199, 10 % FCS Superior (v/v), 1 % P/S (v/v), 1 % L-
Glutamin (v/v), 1 mM CaCl2, filtered sterile and store at 4° C  
Culture medium 
NRVCMs (0.5 % FCS) 
Medium 199, 0.5 % FCS Superior (v/v), 1 % P/S (v/v), 1 % L-
Glutamin (v/v), 1 mM CaCl2, filtered sterile and store at 4° C  
Culture medium for 
HEK293T (10% FCS) 
DMEM (with High Glucose), 1% P/S, 10% FCS Superior, store 
at 4° C 
Culture medium for 
HEK293T (0% FCS) 
DMEM (with High Glucose), 1% P/S, 0.0% FCS Superior, store 
at 4° C 
10x ADS (for isolation of 
NRVCMs) 
1163.3 mM NaCl, 197.2 mM HEPES, 94.2 mM NaH2PO4 x 
H2O, 55.5mM Glucose, 53.6 mM KCl, 8.3 mM MgSO4 x 7 
H2O, adjusted pH with (5M NaOH) to 7.4 
1x ADS with phenol red 
(for isolation of 
NRVCMs) 
450 ml H2O (Aqua ad injectabilia), 50 ml 10x ADS, 50 mg of 
phenol red, filtered sterile and store at 4° C 
1x ADS colorless (for 
isolation of NRVCMs) 
450 ml H2O (Aqua ad injectabilia), 50 ml 10x ADS, filtered 
sterile and store at 4° C 
Percoll-Gradient stock 
solution (for 6 gradients)  
36 ml Percoll, 4 ml 10x ADS, store at 4° C 4°C  
Percoll-Gradient Top-
layer 
13.5 ml stock solution, 16.5ml 1x ADS with phenol red, stored 
at 4° C 
Percoll-Gradient Bottom-
layer 
19.5 ml stock solution, 10.5ml 1x ADS colorless, stored at 4° C 
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4.4 Primers 
Primers for quantitative real time PCR (qRT-PCR) were ordered from Life 
Technologies and they were delivered lyophilized and desalted. 
 
Gene Sequence (5' - 3') Temp. Sp. Template 
ANP Forward TGCCGGTAGAAGATGAGGTC 
63.5° C  
Rat, 
Mouse 
NM_008725.3 
ANP Reverse TGCTTTTCAAGAGGGCAGAT 
β-MHC Forward GCCAACACCAACCTGTCCAAGTTC 
63.5° C  
Rat, 
Mouse 
NM_080728.3 
β-MHC Reverse TGCAAAGGCTCCAGGTCTGAGGGC 
BNP Forward CTGAAGGTGCTGTCCCAGAT 
57° C  
Rat, 
Mouse 
NM_008726.5 
BNP Reverse CCTTGGTCCTTCAAGAGCTG 
Col1a1 Forward GTGTTCCCTACTCAGCCGTC 
57° C  Mouse NM_007742.4 
Col1a1 Reverse ACTCGAACGGGAATCCATCG 
Col3a1 Forward TGACTGTCCCACGTAAGCAC 
57° C  Mouse NM_009930.2 
Col3a1 Reverse GAGGGCCATAGCTGAACTGA 
GNAi2 Forward AGCGTGCGGATGATGCC 
61° C Mouse NM_008138.5 
GNAi2 Reverse TGCGCTCCAGATCATTCAGG 
HPRT1 Forward GAGGAGTCCTGTTGATGTTGCCAG 
55-65° C  Mouse NM_013556.2 
HPRT1 Reverse GGCTGGCCTATAGGCTCATAGTGC 
HPRT1 Forward CTCATGGACTGATTATGGACAGGAC 
55-65° C  Rat NM_012583.2 
HPRT1 Reverse GCAGGTCAGCAAAGAACTTATAGCC 
POSTN Forward ACAAAAGGGTTCAAGGGCCTA 
60° C  Mouse NM_009071.2 
POSTN Reverse TTGGCTTCTGTTGGTTGTCA 
Rel1 Forward CCATGCATTGTTTGTGCCGA 
61° C  Rat NM_201417.1 
Rel1 Reverse TTTGCAGGCACAGCTTTTGG 
Rel1 Forward CGAATGCTTGGTTGGCTCTG 
59° C  Mouse NM_212452.2 
Rel1 Reverse AAGACGCTCACGGAGTGAATC 
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4.5 Antibodies 
4.5.1 Primary antibodies 
 
4.5.2 Secondary antibodies 
 
4.5.3 Secondary antibodies for immunofluorescence 
Name Ratio Sp. System Source 
Goat anti-rabbit IgG (H+L) 
Alexa Fluor® 568 
1:200 Rabbit Olympus Invitrogen, Karlsruhe, Germany 
Goat anti-mouse IgG (H+L) 
Alexa Fluor® 488 
1:200 Mouse Olympus Invitrogen, Karlsruhe, Germany 
 
 
 
 
 
 
 
 
 
Name of Protein Ratio Sp. System Source 
AKT 1:1000 Rabbit LiCor Cell Signaling Technology, Inc. 
Frankfurt am Main, Germany 
ERK 1/2 1:2000 Rabbit LiCor 
 
Cell Signaling Technology, Inc. 
Frankfurt am Main, Germany 
FLAG M2 1:1000 Mouse LiCor Sigma Aldrich, Munich, Germany 
GAPDH 1:10000 Mouse LiCor Merck Millipore, Darmstadt, 
Germany 
P-Akt (Ser473) 1:1000 Mouse LiCor Cell Signaling Technology, Inc. 
Frankfurt am Main, Germany 
P-ERK 1/2 1:2000 Mouse LiCor Cell Signaling Technology, Inc. 
Frankfurt am Main, Germany 
P-PLB (S16) 1:5000 Rabbit LiCor Merck Millipore, Darmstadt, 
Germany 
P-PLB (T17) 1:5000 Rabbit LiCor Badrilla, Leeds, UK 
PLB 1:7500 Mouse LiCor Thermo Fisher Scientific, 
Waltham, USA  
α-Actinin (sarcomeric)  1:2000 Mouse LiCor Sigma Aldrich, Munich, Germany 
Name Ratio Sp. System Source 
Goat anti-mouse IgG (H+L) 
Alexa Fluor® 680 
1:10000 Mouse LiCor Invitrogen, Karlsruhe, Germany 
Anti-rabbit IgG (H+L) 
DyLight(TM)800 
1:10000 Rabbit LiCor Cell Signaling Technology, Inc. 
Frankfurt am Main, Germany 
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4.6 Plasmids 
Denotation Description 
Antibiotic 
Resistant 
pSSV9 CMV MLC260 
FLAG RXFP1 
FLAG RXFP1 recombinant plasmid for 
viral production 
Amp 
pSSV9 CMV MLC260 
FLAG LUC 
FLAG Luciferase recombinant plasmid for 
viral production 
Amp 
pDP9rs Helper plasmid for virus production Amp 
pDP6rs Helper plasmid for virus production Amp 
pCDNA3.1 FLAG RXFP1 Sub-clone plasmid Amp 
pCDNA3.1 FLAG LUC Sub-clone plasmid Amp 
 
4.7 Equipment 
Denotation Source 
ADVANTAGE PV Loop system  Scisense, Ontario, Canada 
Agarose-Gel Chamber Bio-Rad, Munich, Germany  
Autocalve VX-150 Systec, Linden, Germany 
Bacterial Incubator HEREUS, Kleinostheim, Germany 
CFX96 Real-Time system C1000 Touch™ 
Thermal Cycler 
Bio-Rad, Munich, Germany  
ChemiDoc ECL Scanner  Bio-Rad, Munich, Germany  
Echo Vevo 2100  FUJIFILM Sonosite B.V., Amsterdam, 
Netherland 
Electrophoresis unit Bio-Rad, Munich, Germany  
ELISA Reader Multiscan Spectrum  Thermo Scientific, Karlsruhe, Germany 
Fluorescence microscope IX81; CellR MT20  Olympus, Hamburg, Germany 
Freezer (-20° C) Liebherr, Kirchdorf an der Iller, Germany 
Gel Doc XR System Bio-Rad, Munich, Germany  
Hera Safe Laminar Flow Thermo Scientific, Karlsruhe, Germany 
Heracell™ 150i CO2 Incubators with Copper 
Chambers  
Thermo Scientific, Karlsruhe, Germany 
Heraeus Multifige 4 UR  Thermo Scientific, Karlsruhe, Germany 
Light microscope AXIO Vert.A1 Carl Zeiss, Oberkochenm, Germany  
Luminometer Berthold, Bad Wildbach, Germany 
Magnetic stirrer Model L-71  Labor Brand, Gießen, Germany 
Megafuge Sorvall RC6  Thermo Scientific, Karlsruhe, Germany 
NanoDrop™ 2000 Thermo Scientific, Karlsruhe, Germany 
Neubauer counting chamber Hecht-Assistant,  ondheim Rh n, 
Germany 
Odyssey CLX  Licor, Bad Homburg, Germany 
PCR cycler C1000 Touch™ Thermal Cycler  Bio-Rad, Munich, Germany  
pH-Meter MP220  Mettler Toledo, Gießen, Germany 
Pipetboy Neo lab, Heidelberg, Germany 
Pipets  Eppendorf, Hamburg, Germany 
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Scales EW 6000-1M Kern, Balingen, Germany 
SDS-Gel chamber XCell Surelock Invitrogen, Karlsruhe, Germany 
SemiDry Blotter  Bio-Rad, Munich, Germany  
Shaker DRS-12 Neo lab, Heidelberg, Germany 
Spectrophotometer U-2000  Hitachi, Mannheim, Germany 
Table top centrifuge 1-15K  Sigma Aldrich, Osterode am Harz, 
Germany 
Thermomixer 5436  Eppendorf, Hamburg, Germany 
Transilluminator Alpha DigiDoc Alpha Innotech, Santa Clara, USA  
Ultracentrifuge  orvall™ WX Untra  eries Thermo Scientific, Karlsruhe, Germany 
Voltage regulator Power Pac HC  Bio-Rad, Munich, Germany  
Vortex-Genie Neo lab, Heidelberg, Germany 
Water bath E100  Lauda, Lauda-K nigshofen, Germany 
Water purification system TKA-GenPure  Thermo Scientific, Karlsruhe, Germany 
 
4.8 Software  
Program Source Application 
CFX Manager™  Bio-Rad  Analysis of qRT-PCR data 
Echo Vevo 2.0  Visualsonics  Evaluation of echocardiography 
G-power University of Düsseldorf  In vivo experiments power analysis 
Image J (Freeware) National Institutes of Health, 
Bethesda, Maryland  
Histology evaluation and 
quantification 
Image Studio Lite Licor  Odyssey Western Blots 
ImageLab Bio-Rad  ECL Western Blots and agarose 
gels 
Labscribe 2.0  Iworx/scisense  Evaluation of pressure-volume loop 
Office 2016 Microsoft Word, Excel, Powerpoint, Outlook  
Prism 6 GraphPad Illustration of data and statistical 
analysis 
Serial Cloner SerialBasics Analysis of plasmid sequences 
EndNote X9 Clarivate Analytics Reference management 
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4.9 Special materials, assays and kits 
4.9.1 Special materials 
Denotation Description Source 
Surgical Tools Surgical scissors  
 2 fine tip tweezers Fine Science Tools GmbH, 
Heidelberg 
 Scalpel  
 Surgical stapler  
PV Loop PV catheter mouse 112-479 1.2F; 4.5mm 
electrode spacing 
Transonic, Ithaca, USA 
DNA Loading 
Standards 
GeneRuler 100 bp DNA Ladder Thermo Fisher Scientific, 
Waltham, USA  
 100 bp Extended DNA Ladder Carl-Roth, Karlsruhe, 
Germany  
Protein Loading 
Standard 
PageRuler Prestained Protein Marker 10 
to 180 kDa 
Thermo Fisher Scientific, 
Waltham, USA  
Enzymes Restriction enzymes and T4 DNA Ligase New England Biolabs, 
Ipswich, USA 
 Alkaline Phosphatase New England Biolabs, 
Ipswich, USA 
  Benzonase®  Sigma Aldrich, Munich, 
Germany 
 
4.9.2 Assays and Kits 
Denotation Source 
Human Relaxin-2 Quantikine Elisa Kit 
DRL200 
R&D Systems, Minneapolis, USA 
BioMix™ Red PCR Kit Bioline, London, UK 
DC™ (detergen compatible) Protein 
assay 
Bio-Rad, Munich, Germany 
GeneElute™ Plasmid Miniprep Kit Sigma Aldrich, Munich, Germany 
Phusion PCR Kit New England Biolabs, Ipswich, USA 
QIAGEN Plasmid Giga Kit (5).  Qiagen, Hilden, Germany 
QIAGEN Plasmid Maxi Kit (10).  Qiagen, Hilden, Germany 
QIAGEN Plasmid Midi Kit (25).  Qiagen, Hilden, Germany 
QIAquick Gel Extraction Kit  Qiagen, Hilden, Germany 
QIAquick PCR Purification Kit Qiagen, Hilden, Germany 
SignalFire ECL Detection Kit  Cell Signaling Technology, Inc. Frankfurt am 
Main, Germany 
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4.10 Consumables 
Denotation Source 
12 and 24 Well Plate  Corning, Kaiserslautern, Germany 
6 and 96 Well Plate  Greiner bio-one, Frickenhausen, Germany  
96 Well Plate, Lumitrac white Greiner bio-one, Frickenhausen, Germany  
Cell culture dishes ø 145 cm, ø 6 cm Greiner bio-one, Frickenhausen, Germany  
Cell culture Flasks (T 75 cm
2
, and T 175 cm
2
)  arstedt, N mbrecht, Germany 
Cell scraper Greiner bio-one, Frickenhausen, Germany  
Cell stack (10 layers) Corning, Kaiserslautern, Germany 
Cell strainer 100 micron BD, Heidelberg, Germany 
Conical centrifuge tubes, 500 ml  Corning, Kaiserslautern, Germany 
Cryotubes, 1.5 ml Neo Lab, Heidelberg, Germany 
Filter 0.45 μm, 0.22 µm, and 0.33 mm Millex 
GS 
Merck Millipore, Darmstadt, Germany 
Filter paper LLG Lab Logistics Group, Meckenheim, 
Germany 
Immobilon-FL PVDF membrane Merck Millipore, Darmstadt  
Magnetic stir bar Neo Lab, Heidelberg, Germany 
Microscope cover glass round, ø 15 mm  Neo Lab, Heidelberg, Germany 
Microscope superfrost® slide plus Menzel, Braunschweig, Germany 
Microseal B film Bio-Rad, Munich, Germany 
Needles (Microlance: 20G, 21G, 23G, 26G, 
27G) 
BD, Heidelberg, Germany 
Novex Tris Glycin Gele 4-20 %  Life Technologies, Darmstadt, Germany 
PCR Tube 0.2 ml  Kisker Biotech, Steinfurt, Germany 
PCR-Plate 96 Well  Bio-Rad, Munich, Germany 
Plasma collection tube  arstedt, N mbrecht, Germany 
Quick seal tube 13 mL and 40 mL Beckman Coulter, Indianapolis, USA 
Reaction tubes 1.5 ml RNAse-, DNase-, 
Pyrogen free 
Nerbe plus, Winsen/Luhe, Germany 
Reaction tubes 1.5 ml, 2ml   arstedt, N mbrecht, Germany 
Reaction tubes 12 ml, 50 ml  arstedt, N mbrecht, Germany 
Serological Pipettes  arstedt, N mbrecht, Germany 
Silk and prolene suture Harvard Apparatus, Holliston, USA  
 terile filter 0.22 μm, 0.45 µm and, 0.33 mm 
Millex GS  
Merck Millipore, Darmstadt, Germany 
Sterile pipette Tips  arstedt, N mbrecht, Germany 
Syringe 1 mL, 2 mL, 5 mL, 10 mL, 50 mL BD, Heidelberg, Germany 
Test tubes 5 ml  arstedt, N mbrecht, Germany 
Transfer membranes with 0.45 μm pore Merck Millipore, Darmstadt, Germany 
Whatman paper GE Healthcare, Freiburg, Germany 
Zeba Spin Desalting columns  Thermo Fisher Scientific, Waltham, USA  
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4.11 Methods 
4.11.1 Cloning 
 
Figure 9: DNA fragments and plasmid construct used for cloning. 
(A) Fragment of RXFP1 construct used to sub cloned into AAV transfer plasmid, (B) 
pCDNA3.1 FLAG plasmid with restriction sites of interest, and (C) AAV transfer plasmid 
with restriction sites of interest.  
 
The recombinant AAV vectors of serotypes 6 and 9 CMV MLC260 FLAG Rel1
Rattus
 
(designated AAV6 RXFP1 or AAV9 RXFP1) were generated as follows. The FLAG-TAG 
Rattus Norvegicus Rel1 cDNA [NM_201417.1, National Center for Biotechnology 
Information (NCBI)] was synthesized and sub-cloned into a pCDNA3.1 plasmid. After 
extensive testing in a cell line, the transgene cassette was subcloned into an AAV transfer 
plasmid between a synthetic cardiac myocyte-specific cytomegalovirus (CMV) enhancer, 
short (260bp) myosin light chain promoter and a bGH pA, which is flanked by two ITRs 
from AAV2. Figure 9 shows RXFP1 DNA fragment and different plasmid construct used for 
cloning. 
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4.11.1.1 DNA Digestion 
 
Figure 10: Agarose gel purification. 
Agarose gel containing fragments of LUC, RXFP1 and PSSV9 AAV transfer plasmid  
 
In general, 1 µg of DNA was used in all restriction digests. 1 unit of restriction 
endonuclease was used in order to complete DNA digestion. A 40 µL total digestion volume 
was set up for all digestions. To completely digest all the DNA, the solution was incubated at 
37° C for 3 hours and the reaction was quenched at 80° C for 20 minutes. For the backbone 
plasmids, 10 unit of alkaline phosphatase was used in order to prevent re-ligation of the 
plasmids. The mixture was incubated for 1 hour and the enzyme was denatured for 20 
minutes at 95° C. Gel electrophoresis was used to separate the correct DNA fragments. 1 
percent agarose gel was run at 100 V for 1 hour 30 minutes. A correct DNA fragment was 
excised from the gel under UV lamp and a gel isolation kit was used in order to recover the 
fragment from the gel (Figure 10). A final clean up step using a PCR clean up kit was 
performed in order to remove as much agarose as possible. DNA was eluted in sterile water 
and used for cloning afterward. The DNA was kept as concentrated as possible after the 
digestion step. For long term storage, the DNA was frozen in a TE buffer with low EDTA in 
order to prevent degradation.  
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4.11.1.2 DNA Ligation 
An Online ligation calculator from New England Biolab (NEB) was used to set up all 
ligation reactions. 100 ng of backbone plasmid was used in every reaction. The amount of 
insert used was varied from reaction to reaction due to the different ratios between the 
backbone and insert. Generally, the ratio of 1:3 (backbone to insert) was kept in all reactions. 
1 unit of DNA ligase was used for a 20 µL reaction. The reaction was incubated at 16° C 
overnight and the ligase was denatured at 85° C for 20 minutes before transformation.  
 
4.11.1.3 Transformation 
Chemically competent E. coli (DH5) bacteria were purchased from NEB. A simple 
heat shock protocol was used, including 35 minutes of incubation of the bacteria and plasmid 
on ice, then a 2 minutes heat shock at 42° C. Then a 5 minutes recovery period on ice and a 1 
hour aerated incubation period at 37° C using SOC medium. The culture was concentrated 
and 100 µL was plated onto a respected antibiotic agar plate. The plate was incubated in a 
37° C oven overnight before 4 to 5 colonies were picked for further characterization.  
 
4.11.1.4 Gel electrophoresis 
% Agarose 
Optimum Resolution for Linear 
DNA 
0.7 800-12,000 bp 
1 500-10,000 bp 
1.5 200-3,000 bp 
2 50-2,000 bp 
Table 2: Optimum agarose concentration for different sizes of linear DNA 
 
Gel electrophoresis was utilized to detect digested DNA fragments. Different amounts 
of agarose (w/v) were added to 100 mL of TAE buffer. Depending on the size of the 
fragments of interest the percentage of the gel ranged from 0.6% to 2%. Table 2 shows the 
corresponding percentage of gel to DNA fragment size observed. The mixture was then 
heated up in the microwave at high heat for 2 minutes. 10 µL of ethidium bromide was added 
to the mixture (1:10,000) and the mixture swirled to mix. The gel was casted into the casting 
chamber, bubbles were removed, the comb was inserted. The gel was left to cool down at 
room temperature for 45 minutes. The comb was carefully removed, and the gel placed into 
the electrophoresis chamber. DNA was loaded onto the gel and was allowed to run at 120 V 
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for 45 minutes at room temperature. After the run, the gel was scanned using a Bio-Rad gel 
DOC XR system. 
 
4.11.1.5 Screening for a correct clone and plasmid preparation 
To screen whether the bacteria contained the correct insert, 3-5 bacteria colonies were 
picked from the transformed population and each inoculated into 5 mL of LB medium 
containing the appropriate antibiotic (100 mg/mL). The cultures were grown overnight in a 
37° C incubator. The next morning a Sigma mini-prep kit was used to isolate plasmid DNA 
from the bacteria cultures.  
 Midi-prep Maxi-prep Giga-prep 
Culture volume 
(mL) 
100 600 6,000 
P1 buffer (mL) 4 10 120 
P2 buffer (mL) 4 10 120 
P3 buffer (mL) 4 10 120 
Incubation time 
(min) 
15 20 30 
QTB buffer (mL) 4 10 75 
QC buffer (mL) 20 60 600 
Isopropanol (mL) 3.5 10.5 70 
70% EtOH (mL) 2 5 10 
H2O (µL) 150 500 2,000 
 
Table 3: Different scales preparation of plasmid DNA using Qiagen kit 
 
Overnight bacteria cultures were pelleted separately into a 1.5 mL Eppendorf tube 
using a benchtop centrifuge. The supernatant was discarded, and the pellets were re-
suspended with 200 µL of P1 re-suspension buffer. 200 µL of P2 lysis buffer was added to 
each tube and the tubes were inverted several times until the mixture turned viscous. 350 µL 
of P3 neutralization buffer was added to each tube and the tubes were inverted several times 
until white flocculates appeared. To obtain clean bacteria lysate, the mixture was centrifuged 
at 13,000 rpm for 10 minutes at room temperature in order to pellet all precipitates. 
Meanwhile 500 µL of column preparation buffer was added to each column and centrifuged 
through using a benchtop centrifuge. The flow through was discarded and the bacteria lysate 
was added to each prepared column. The columns were centrifuged at 13,000 rpm for 1 
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minute at room temperature and the flow through discarded. 500 µL of wash solution 1 was 
added to each column and the columns were centrifuged at 13,000 rpm for 1 minute at room 
temperature and the flow through discarded. 750 µL of wash solution 2 was added to each 
column. The columns were centrifuged at 13,000 rpm for 1 minute at room temperature and 
the flow through discarded. The columns were centrifuged at 13,000 rpm for 2 minutes at 
room temperature to remove all trace of alcohol. The columns were separately placed onto 
new 1.5 mL Eppendorf tubes and 35 µL of ddH2O was added. The column was incubated for 
3 minutes at room temperature and centrifuged at 13,000 rpm for 1 minute at room 
temperature to elute all the plasmid DNA. The obtained plasmid DNA concentration was 
measured using a nanodrop and 500 ng of plasmid DNA was used for restriction digest with 
appropriate enzyme in order to confirm the correct clone.  
Higher amounts of plasmid DNA were needed for virus production. Qiagen plasmid 
Midi, Maxi and Giga kit were used. Generally, midi-prep and maxi-prep were used for small 
scale virus production and giga-prep was used for large scale virus production. Manufacturer 
instructions were followed. Table 3 below shows buffers, volumes and incubation times used 
for each plasmid kit.  
4.11.2 Virus Production 
Recombinant vector productions were generated by cross-packaging of AAV2-
inverted terminal repeat recombinant genomes into AAV6 or AAV9 capsids using the two 
plasmids transfection protocol described by [133, 134]. High titer vectors were produced 
using 150 mm cell culture dishes or cell stacks (Corning) with polyethylenimine harvested 
after 48 hours and purified by filtration and iodixanol gradient as described by [135]. The 
recombinant adeno-associated viral vectors AAV6 and AAV9 CMV MLC260 FLAG 
Rel1
Rattus
 (designated AAV6 RXFP1 or AAV9 RXFP1) and control virus vector AAV6 and 
AAV9 CMV MLC260 FLAG Luc
Firefly
 (designated AAV6 LUC or AAV9 LUC) were 
generated using the described method. Viral titers from both viruses were quantified at the 
same time using a SYBR-green quantitative real time PCR (qRT-PCR) assay and expressed 
as viral genomes per milliliter (vg/mL). Figure 11 shows the plasmid used for virus 
production and in silico analysis of RXFP1 protein structure with added FLAG-TAG. 
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Figure 11: RXFP1 transgene construct.  
(A) RXFP1 transgene expression cassette with FLAG-TAG and cardiac specific promoter. 
(B) Plasmid map of the RXFP1 construct cloned into pCDNA 3.1 plasmid (Serial cloner). 
(C) In silico analysis of RXFP1 protein folding with FLAG-TAG modification. 
 
4.11.2.1 Small scale virus (AAV) production 
For in vitro experiments, small scale productions of AAV serotype 6 were used [136]. 
HEK 293T cells were seeded in a T175cm
2
 cell culture flask with 3 x 10
6
 cells in 20 mL of 
medium. Four flasks were needed to complete one small scale production. 48 hours after 
seeding, the cells were split into sixteen 150 mm dishes with approximately 8.5 x 10
6
 cells 
per dish. One day after seeding the dishes, the cells were transfected with polyethylenimine 
(PEI), AAV helper plasmid DNA and the respective AAV genome plasmid DNA. Table 5 
below shows the volume of buffer, PEI and the amount of DNA needed for each production. 
The mixture was mixed in the order shown in Table 5 and incubated at room temperature for 
20 minutes before the full medium was added. The medium from all the dishes was removed 
and 15 mL of the transfection mixture was added to each dish. The cells were incubated for 3 
days at 37° C (5% CO2). After the incubation period, the cells were harvested along with the 
medium. The dishes were washed with PBS and the cells from the medium and wash were 
pelleted by centrifugation at 2000 rpm for 15 minutes at room temperature. All the pellets 
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were combined, and the cells were re-suspended in 5 mL of lysis buffer containing protease 
inhibitor. The cells were lysed by freeze/thaw cycles. Re-suspended cells were frozen in 
liquid nitrogen for 10 minutes and thawed at 37° C for 10 minutes. The cycle was repeated 4 
times. The genomic DNA and other DNA contaminant were digested using Benzonase ® 
nuclease (50 U per mL lysis buffer) for 1 hour at 37° C. The AAV containing cell lysate was 
centrifuged for 30 minutes at 4400 rpm to pellet the remaining cell debris. The supernatant 
was transferred to a new tube and stored in the -20° C until further gradient purification was 
performed.  
 
4.11.2.2 Large scale virus (AAV) production 
Large scale virus production was done using a 10 layered cell stack production unit 
according to [135, 137]. Only AAV serotype 9 was produced in large scale for the in vivo 
study. Six T175 cm
2
 flasks were seeded with 3x10
6
 HEK293T cells each.  The cells were 
incubated at 37° C with 5% CO2 for 48 hours. Six flasks were split and 2.3x10
8
 cells were re-
suspended in 1,040 L of complete medium. One liter of the cell mixture was added to the 10 
layered cell stack. The last 40 mL of the cell mixture was split in half and 20 mL was seeded 
as negative and positive controls accordingly. The cells were incubated at 37° C with 5% 
CO2 for 16 hours. The following day, after seeding, transfection was performed using 400 µg 
of recombinant AAV genome DNA and 1,525 µg of helper plasmid (pDP9rs) mixed with 800 
mL serum free medium and 15.5 mL of transfection reagent PEI (Table 4). The DNA mixture 
was added to a serum free medium and mixed well before PEI was added. The mixture was 
incubated at room temperature for 20 minutes. 220 mL of full medium was added to the 
mixture after incubation. The medium from the cell stack was removed and 1.02 liters of the 
transfection mixture was added to the cell stack. The remaining 20 mL was added to the 
positive control flask. The cell stack was gently inverted to mix the transfection reagent. The 
cells were incubated at 37° C with 5% CO2 for 48 to 60 hours before harvesting 
After 72 hours the positive and negative controls were checked under the microscope. 
At least 40 percent of the cells have to detach in order to harvest the production. If the 
positive control met the criteria and the negative control showed healthy cells, the production 
was harvested. The cells were checked again after 12 hours. To harvest the cells, all medium 
was removed from the cell stack into 500 mL bottle. 300 mL of PBS was used to wash the 
cell stack. The cells were detached using a solution of 50 mL PBS/EDTA and 50 mL 0.25% 
trypsin. The cell stack was incubated for 5 minutes at 37° C. After 5 minutes, the cell stack 
tapped on the bench to facilitate the detachment of the cells. When all cells were detached, 
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300 mL of old medium was added to stop the reaction. All cells and medium were 
centrifuged at 4,400 rpm for 5 minutes at 4° C. After centrifugation, the supernatant was 
transferred to a glass bottle containing 331 g/L ammonium sulfate. The supernatant mixture 
was incubated overnight at 4° C with constant stirring at 1,000 rpm. The next morning the 
mixture was centrifuged at 4,400 rpm for 35 minutes at 4° C. The supernatant was removed, 
and the pellet was resuspended in 20 mL of lysis buffer containing 1x protease inhibitor then 
stored in - 20° C. The cell pellet was re-suspended by vortexing in 5 mL of lysis buffer 
containing 1x protease inhibitor and store at - 20° C.  
 
Small Scale 
(12 dishes) 
Large Scale (10 
layers cell stack) 
Serum Free Medium 
(mL) 
120 800 
Amount of AAV genome 
plasmid (µg) 
150 400 
Amount of helper AAV 
plasmid (µg) 
750 1,525 
PEI (mL) 2.2 15.5 
Full medium with 10% 
FCS (mL) 
60 220 
Incubation time (min) 20 20 
Amount added to each 
dish or cell stack (mL) 
15 1,000 
Table 4: Transfection reagents and volumes used in different scales of viral production 
 
 The cells were lysed by freeze/thaw cycles. The cell pellet was frozen in liquid 
nitrogen for 5 minutes, then thawed in room temperature water for 5 minutes, and further 
thawed in 37° C warm water for 5 minutes. After all the steps, the cells were vigorously 
vortexed for 1 minute. The cycle was repeated 4 times in order to effectively lyse the 
majority of the cells. Contamination from genomic DNA and unpackaged viral DNA was 
addressed by adding Benzonase
® 
nuclease (50 U per mL lysis buffer) and incubating the 
mixture at 37° C for 1 hour. The lysate was cleaned by centrifugation at 4,400 rpm for 45 
minutes at 4° C. After centrifugation, the clear supernatant containing AAV particles was 
transferred into a new tube and the pellet was discarded. This step was repeated until no more 
pellet could form from the supernatant after centrifugation. The clean supernatant was kept at 
4° C before purification. 
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4.11.2.3 Iodixanol density gradient 
Iodixanol density gradient was used to purify AAV particles from cell lysate for both 
small-scale and large-scale viral production (Figure 12) [138].  
 
Figure 12: Iodixanol gradient. 
Example of how to set up Iodixanol gradient and how to locate virus after centrifugation  
 
 The AAV particle was purified from the cell lysate using an iodixanol density 
gradient. First, AAV containing lysate was filled into an ultra-centrifugation tube using a 
Pasteur pipette. (15%) iodixanol solution, (25%) iodixanol solution, (40%) iodixanol 
solution, and (60%) iodixanol solution were added using the underlaying technique. Table 5 
below summarizes the loading of both small and large iodixanol gradient.  
 Small Gradient (mL) Large Gradient (mL) 
Samples 5 20 
(15%) iodixanol solution 2 7 
(25%) iodixanol solution 2 5 
(40%) iodixanol solution 2 4 
(60%) iodixanol solution 2 4 
Table 5: Iodixanol density gradient loading for small and large scale AAV production 
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The ultra-centrifugation tubes were heated, sealed and balanced carefully to a margin 
of error of less than 20 mg between the balanced pair. The samples were centrifuged at 
50,000 rpm for 2 hours at 4° C. After centrifugation, the tubes were carefully removed from 
the rotor and the AAV particles were collected using a syringe with a 21-gauge needle. The 
AAV particles containing layer (Figure 11) located between the 60% and 40% iodixanol was 
removed with an approximate volume of 1 mL per small scale gradient and 3 mL per large 
scale gradient. The collected AAV particles were desalted using a 10 mL Zebra spin desalting 
column. Manufacture’s protocol was followed, in order to exchange iodixanol to PBS. The 
obtained AAV particles were stored at 4° C for short term storage and -20° C for long term 
storage. For long term storage, the virus was concentrated before being frozen.  
 
4.11.2.4 Virus titration 
AAV vector genomes were quantified using qRT-PCR method against AAV standard 
kindly provided by AG Müller [135, 139]. AAV vectors were diluted 1:100 in ddH2O. The 
diluted samples were mixed with 10 µL TE buffer and 20 µL 2 M NaOH solution. The 
samples were incubated at 56° C for 30 minutes and neutralized with 960 µL 40 mM HCl 
solution. AAV vector standard was diluted ranging from 10
3
 to 10
9
 vg/well. SYBR green 
supermix was used for the qRT-PCR reaction. All samples including the standard were 
quantified in triplicate using a 96-well plate. Each standard well contains 10 µL of SYBR 
green supermix, 0.5 µL of SV40 forward primer (10 pmol/µL), 0.5 µL of SV40 reverse 
primer (10 pmol/µL), 6 µL of ddH2O, and 3 µL of standard vector. Each sample well 
contains 10 µL of SYBR green supermix, 0.5 µL of SV40 forward primer (10 pmol/µL), 0.5 
µL of SV40 reverse primer (10 pmol/µL), 6 µL of ddH2O, and 3 µL of sample. The final 
volume in each well is 20 µL. A No-Template-Control with water was included in every 
experiment in order to minimize occurrence of false positive samples. The PCR plate reader 
was programed as followed (Table 6). 
Step Temperature Time Number of Cycles 
Denaturation 95° C 1:00 1x 
Denaturation 
Annealing and reading 
95° C 
60° C 
0:05 
0:30 
40x 
Melting Curve 
65  95° C with 0.5° C 
increment 
0:05 60x 
Table 6: qRT-PCR program for AAV vectors quantification 
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The obtained results were analyzed using CFX manage software from Bio-Rad. A 
standard curve was plotted from the obtained results and the titer was calculated in Microsoft 
excel using an equation obtained from the best fit line of the standard.  
 
4.11.3 Cell Culture techniques  
Aseptic techniques were used to ensure sterile. The HEK293T cell line was kindly 
provided by AG Most. The cells were grown and preserved in liquid nitrogen at passage 8. 
HEK cells were generally cultured in a T75 flask or a T175 flask depending on the amount 
required for the experiment. Primary cells were cultured for a maximum of 7 days in 6-well, 
12-well or 96-well plates depending on the experimental set up.   
 
4.11.3.1 Cell line culture techniques 
A HEK293 cell line was also used for this study. The cells were cultured in DMEM 
medium with high glucose supplemented with 10% v/v FCS, 100 U/mL penicillin, AND 100 
µg/ streptomycin. This cell line was cultivated in sterile 75 cm
2
 or 175 cm
2
 culture flasks 
which were lying horizontally in a humidified incubator containing 37° C and 5% CO2. The 
cells were split every two days or when the monolayer reached at least 80 % confluence. To 
split the cells, the medium was removed, and the cells washed with 10 mL of warm PBS. 
PBS was removed and 4 mL of 0.25% Trypsin EDTA was added to the bottle for 4 minutes. 
Then 6 mL of full 10% FCS medium was added to stop the digestion. The cells were pipetted 
up and down at maximum speed for 7 times.  To reseed the bottle, 1 mL containing 3.5 
million cells was seeded into a new bottle and 20 mL of full medium was added (Table 8). 
The cells were discarded after reaching passage 35.  
4.11.3.2 Seeding of the cell line 
After splitting, HEK293T cells were seeded into multi-well plates for in vitro 
experiments, then reseeded for maintenance of the culture into culture a flask. The Neubauer 
improved cell counter technique was used to determine the amount of cells in the suspension. 
First the suspension was diluted 1:10. Then 10 µL was loaded onto the Neubauer chamber. 
The cells in all four major squares with 16 smaller squares were counted. The average 
number of cells counted was calculated and the amount of cell per mL could be calculated 
with the following formula. 
 
(Average cell counted) x (dilution factor of 10) x 10
4
 = number of cells per mL 
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 Table 7 shows the numbers and volumes of cells seeded in different plates and flasks 
 Area per well (cm
2
) 
Number of cells 
seeded 
Final volume (mL) 
6-well plate 10 3 x 10
5 
2 
12-well plate 4 1.5 x 10
5 
1 
24-well plate 2 7 x 10
4 
0.5 
T175 cm
2
 flask 175 3 x 10
6
 21 
T75 cm
2
 flask 75 1.5 x 10
6
 12 
T25 cm
2
 flask 25 5 x 10
5
 5 
Table 7: Volumes and numbers of HEK293T cells seeded in different plates and flasks  
 
4.11.3.3 Transfection of HEK293T cells 
Transfection was done on HEK293T cells in order to check the expression level of 
overexpressed protein and the quality of the plasmid DNA produced. One day after seeding 
The HEK293T cells, plasmid DNA was transfected into the cell using Polyethylenimine 
(PEI) transfection reagent. A mixture of 1µg of plasmid DNA, sterile water, 300 mM NaCl 
and PEI was mixed, incubated for 15 minutes at room temperature, and added to the cells 
drop-wise. The plate was gently rocked in order to achieve equal distribution of transfection. 
The cells were incubated for 48 hours at 37° C and 5% CO2 humidified atmosphere. Table 8 
shows the amount of plasmid DNA and mixture volume used for each well. 
 6-well plate 12-well plate 
Volume of sterile H2O (µL) 48 25 
Volume of 300 mM NaCl 
(µL) 
64 30 
Amount of Plasmid DNA 
(µg) 
1 (µg) 1 (µg) 
 Mixed well 
Volume of PEI (µL) 18 9 
Final volume added (µL) 120 90 
 
Table 8: Volumes of DNA and transfection reagent used for HEK293T cells transfection 
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4.11.3.4 Cryopreservation of cells 
To cryopreserve the HEK293T cell line, the cells were resuspended in 8 mL of fresh 
medium after trypsin exposure. The mixture was centrifuged for 10 minutes at 1,500 rpm. 
The supernatant was removed, and the cells were re-suspended in 1 mL freezing medium 
(90% FCS and 10% DMSO). The cell suspension was transferred into cryo-tubes and placed 
into a freezing box containing DMSO which would lead to more gradual and unified 
freezing, in order to prevent growing crystal ice. The tubes were frozen in the -80° C for at 
least 2 days before being thawed for future usage. The frozen cells were removed and stored 
into liquid nitrogen for further storage.  
 
4.11.3.5 Isolation of neonatal rat cardiomyocytes (NRVCMs) 
Primary cultures of neonatal rat ventricular cardiac myocytes (NRVCMs) were 
prepared from 1-2 days old Wistar rats (Charles River) [140, 141]. The neonatal rats were 
euthanatized by decapitation and the heart removed and placed in 1x cold ADS solution. The 
atria and other vessels were removed, and the hearts were transferred into a new 1x cold ADS 
solution. The ADS solution was removed, and the ventricles were washed with 3 mL of cold 
ADS before being minced. Tissue fragments were digested in a T75 bottle with 30 mL of a 
digestion solution containing collagenase and pancreatin for 5 minutes at 37° C. The tissue 
fragments were allowed to settle on side of the bottle and the solution removed and 
discarded. Fresh digestion solution was added, and the tissue fragments were digested for 20 
minutes at 37° C. After 20 minutes, the tissue fragments were pipetted up and down 5 times 
at maximum power and the solution removed and filtered through a 40 µm cell strainer into a 
50 mL falcon. 10 mL of FCS was added through the cell strainer and the solution was 
centrifuged at 1,000 rpm for 5 minutes at room temperature. After centrifugation, the 
supernatant was removed, and 7 mL of FCS was added. The cell solution was placed in a 37° 
C incubator awaiting further processing.  The tissue fragments were digested at least 5 times 
in order to completely dissolve all the tissue pieces. After the digestion, all cell suspensions 
were combined, and centrifuged 1,000 rpm for 5 minutes at room temperature. The 
supernatant was removed, and the cells were resuspended in 12 mL of 1x cold ADS. The 
fibroblasts and cardiac myocytes were separated using a percoll density gradient. 
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4.11.3.6 Separation of NRVCMs from fibroblasts 
To obtain cardiomyocytes with high purity, a two-layer Percoll density gradient was 
performed [140 ]. The gradient consisted of 63% red Percoll solution, and a 40.5% clear 
Percoll solution. 4 mL of red Percoll solution was added into each 15 mL falcon. Then 3 mL 
of clear Percoll solution was added using the underlaying technique. Lastly, 2 mL of cell 
solution containing 1x cold ADS was layered at a 45 degrees angle onto of the gradient. The 
tubes were centrifuged at 2,400 rpm for 30 minutes at 4° C with deceleration speed of 0. The 
upper stromal cells band including fibroblasts was removed by aspiration.  The lower 
cardiomyocytes band was kept and washed twice with 1x cold ADS before being re-
suspended in warm Medium 199 supplemented with 10% v/v FCS, 100 U/mL penicillin, 100 
µg/ streptomycin, 2 mM L-glutamine, and 1 mM calcium chloride. The cells were counted 
manually in a Neubauer chamber and plated accordingly. The NRVCMs were cultured at 37° 
C and 5% CO2 humidified atmosphere. After 48 hours fetal calf serum was reduced to 0.5% 
and cells were cultured for 2-5 days. 
 
4.11.3.7 Cultivation of NRVCMs 
 Area per well (cm
2
) 
Number of cells 
seeded 
Volume per well (mL) 
6-well plate 10 2 x 10
6 
2 
12-well plate 4 5 x 10
5 
1 
96-well plate 0.32 2 x 10
4 
0.1 
Glass bottom 
dish 
3.14 2 x 10
5
 2 
Table 9: Volumes and numbers of NRVCM cells plated on different types of plate 
 
The NRVCMs were cultured at 37° C and 5% CO2 humidified atmosphere. The cells 
were kept in medium M199 (Sigma Aldrich) supplemented with 10% v/v FCS, 100 U/mL 
penicillin, 100 µg/ streptomycin, 2 mM L-glutamine, and 1 mM calcium chloride. Table 9 
shows the number of cells plated for different plate types. Two days after the cells were 
plated, the medium was removed, and the cells were washed once with warm PBS before 
starving medium M199 supplemented with 0.5% FCS, 1% penicillin/streptomycin, 1% L-
glutamine, 1 mM CaCl2 was added. From this point on, the medium was changed every two 
days until the cells were harvested. Usually cells were used for a maximum of 7 days before 
being discarded.  
Materials and Methods 
 57 
 
4.11.3.8 Transduction 
After confirming the expression of the overexpressed protein in the HEK293T cell 
and the AAV vector was produced, the NRVCMs were transduced using AAV vectors two 
days after seeding. AAV6 vectors from small-scale virus productions at the MOI of 1x10
4
 
vg/cell were used in transduction experiments. Two days after seeding, the full medium was 
removed, and the cells were washed with warm PBS to remove as much serum and cell 
debris as possible. Starving Medium 199, supplemented with 0.5% v/v fetal calf serum, 100 
U/mL penicillin, 100 µg/ streptomycin, 2 mM L-glutamine, 1 mM calcium chloride, and the 
respective amount of AAV6 vectors was added onto the cell. AAV vectors were allowed to 
transduce the NRVCMs for 48 hours at 37° C and 5% CO2 before the medium was changed. 
The medium was changed every two days and the cells were stimulated and harvested five 
days after transduction. 
 
4.11.4 In vivo experimental protocols 
All animal procedures and experiments were performed in accordance with the Guide 
for the Care and Use of Laboratory Animals from the National Institutes of Health (NIH) and 
approved by the local Animal Care and Use Committee of Baden-Württemberg, Germany.  
 
4.11.4.1 Administration of AAV vectors by tail vein injection 
Systemic administration of AAV vectors containing the transgene was performed via 
the tail vein [107]. Before injection, mice were put into a restrainer and their tails were 
warmed in a 37° C water. When the vein was visible, a total of 100 µL of viral AAV vector 
was injected intravenously (i.v.) via the tail vein (injection by KEB employees at the animal 
facility of University of Heidelberg). The vectors were allowed to transduce the targeted cells 
for four weeks before further experiments were performed on the mice. 
 
4.11.4.2 Alzet® osmotic pumps implantation 
To continuously administer relaxin, Alzet® osmotic pumps (Alzet® model 1004) 
were used. A final volume of 100 µL was filled into each osmotic pump under sterile 
conditions. The pumps were then implanted subcutaneously (s.c.) into the dorsal side of the 
mice. To decrease the probability of infection, the mice were shaved at the surgical site under 
anesthesia before the operation. 5% isoflurane mixed with 0.5 -1.0 L/min 100% O2was used 
to induce anesthesia in the induction chamber. 0.5% of isoflurane mixed with 0.5 -1.0 L/min 
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100% O2 was administered via a face mask in order to maintain anesthesia after induction. 1 
cm incision was made into the skin of the mice using surgical scissors. Utilizing the blunt 
edge of the scissors, the skin was separated from the muscle to accommodate the pump. The 
pump was cleaned with cleaning solution before being implanted subcutaneously into the 
mice. After implantation, a surgical stapler was used to close the wound. Anti-inflammatory 
drug, carprofen (5µg/g), was given to the mice via intraperitoneal (i.p.) injection. The mice 
were checked every day for the next 5 days. The staple was removed on day 5 and the mice 
were kept for 3 weeks. After 3 weeks the mice were sacrificed, and the organs and plasma 
collected.  
 
4.11.4.3 Echocardiography 
Echocardiography was performed using the Vevo 2100 imaging system from 
Fujifilm-VisualSonics. First, the mice were shaved on the chest using Veet® hair removal 
cream. The conscious mice were held in prone position. Warm ultrasound coupling gel (37° 
C) was placed on the shaved chest area, and the MS400 transducer was positioned to obtain 
2D B-mode parasternal long and short axis views and 1D M-mode short axis view. The 
ejection fraction (EF), fractional area change (FAC), and heart rate (HR) were calculated in 
the B-mode, both long and short axis, using THE LV trace function.  Fractional shortening 
(FS) and left ventricular internal diameter (LVIDd) were calculated from 6 consecutive 
heartbeats in the M-mode using the LV trace function. Figure 13 shows representative images 
of different types of echocardiogram. 
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Figure 13: Different mode of echocardiography 
Representative echocardiogram from 2D B-mode parasternal (A) long axis, (B) short axis, 
and (C) M-mode short axis.  
 
4.11.4.4 Pressure-volume loop (PV loop) 
Mice were anesthetized using a cocktail containing Xylazine (10 µg/g) and Ketamine 
(100 µg/g). 75 µL to 100 µL was injected i.p. into each animal depending on the weight of 
the animal. After 30 minutes, the mice were fixed onto the heating plate in supine position. 
The body temperature was maintained at 37° C. Mice were catheterized through the left 
carotid artery with a 1.2 Fr catheter, and pressure volume loops were measured in the left 
ventricle. Real time data was observed using the ADVantage PV system. All obtained data 
were recorded using a Scisense 404 – 16 Bit Four Channel Recorder with LabScribe2 
software. Parameters such as dP/dtmax and dP/dtmin were calculated.  
 
4.11.4.5 Trans-aortic constriction (TAC) model 
A pressure overload heart failure model was generated by TAC surgery [142, 143]. 8 
weeks old C57BL/6 mice were shaved from the neckline to mid chest level and echoed one 
day before the surgery. 75 µL of an anesthetic cocktail of Xylazine (10 µg/g) and Ketamine 
(100 µg/g) was used to induced anesthesia. The mice were restrained on the heating plate in 
supine position. The mice were then intubated, and anesthesia was maintained with 0.5% 
isoflurane mixed with 0.5 -1.0 L/min 100% O2. A partial thoracotomy to the second rib was 
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performed under a surgical microscope and the sternum retracted using a chest retractor. 
Forceps were used to gently separate the thymus and fat tissue from the aortic arch. After the 
transverse aorta was identified, a small piece of an 8.0 prolene suture was placed between the 
innominate and left carotid arteries. Two loose knots were tied around the transverse aorta. A 
small piece of a 26-gauge blunt needle was placed parallel to the transverse aorta. The first 
knot was quickly tied against the needle, followed by the second and the needle was carefully 
removed in order to yield a constriction. Next the chest retractor was removed, and the 
outflow of the ventilator pinched off for 2 seconds to re- inflate the lungs. The rib cage and 
the skin were closed using a 6.0 prolene suture with an interrupted suture pattern. After the 
surgery, the mouse was injected with carprofen (5µg/g) s.c. Lastly, anesthesia was turned off, 
and the mice were extubated when signs of spontaneous breathing had occurred. The mice 
were placed into prone position and kept on the heating plate to recover for 45 minutes - 1 
hour. In the sham control mice, the entire procedure was identical except for the ligation of 
the aorta. Figure 14 shows the scheme of how TAC operations were performed.  
 
Figure 14: TAC operation scheme 
The scheme of TAC operation starting from 1) initial anesthesia, 2) intubation, 3) TAC 
operation, 4) Suturing and recovery and, 5) post-op follow up and HF development.   
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4.11.4.6 Sample collection and histology 
Before being euthanized, a final blood collection was taken from the mice, and EDTA 
plasma was collected by centrifuging whole blood at 3,000 x g for 15 minutes at 4° C. At the 
end of the study all mice were euthanized by cervical dislocation. The chest was opened, and 
the heart and lungs removed. The heart was washed in cold PBS, weighed and cut into 7 
pieces (Figure 15). The lungs were cleaned and weighed. Other organs such as liver, kidney, 
adrenals, spleen, and skeletal muscle were collected also collected. All tissue pieces were 
gradually frozen on dry ice and placed in the -80° C freezer for further analysis.  
For histology, the second piece of the heart was put into 4% formaldehyde, and kept 
overnight at 4° C. The next morning the tissues were given to the histology core unit at the 
University of Heidelberg for further processing and staining. 
 
Figure 15: In vivo heart sampling diagram.  
The heart was divided into 8 samples according to this diagram. First the atria were removed 
follow by the right ventricle. Lastly, the left ventricular was divided into 6 pieces. The apex 
was used for RNA quantification and the lateral wall of the left ventricle was used for protein 
quantification. 
 
4.11.4.7 Relaxin receptor gene therapy study design 
Eight weeks old C57BL/6 mice were echoed and weighed one day before the start of 
the experiment. The TAC operation was performed on day 1 and the mice were allowed to 
recover for seven days. At day 7, the second echo was performed on the mice to verify the 
operating results. Next the mice were randomly assigned into 4 test groups and 2 sham 
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groups. The virus was injected into the mice via the tail vein on the following day. The virus 
was allowed to express for 4 weeks. At 3 weeks after TAC, and before osmotic pump 
implantation, the mice were assessed again by echocardiogram. The osmotic pumps 
containing relaxin were implanted subcutaneously into the back of the mice. The mice were 
followed for 4 more weeks before being sacrificed.  
 
4.11.4.8 Relaxin H2 measurement 
Circulating levels of recombinant relaxin H2 was measured using a ready to use 
relaxin H2 Quantikine ELISA kit from R&D Systems (DLR200). The plasma samples were 
diluted 1:200 as suggested by the manufacturer. The manufacturer’s protocol was followed. 
50 µL of negative control, positive control, standard, and samples were added to the wells 
that were pre-coated with RLN H2 capture antibody. After 2 hours of incubation at room 
temperature, the wells were thoroughly washed 4 times. Conjugated antibody against RLN 
H2, coupled with horseradish peroxidase, were added into each well and incubated again at 
room temperature for 2 hours. After 2 hours, the conjugated antibody was discarded, and the 
wells were thoroughly washed 4 more times. Next, a freshly made substrate solution was 
added to each well and incubated for 30 minutes at room temperature protected from light. 
The solution color within the wells gradually turned blue. After 30 minutes, the stop solution 
was added, and the solution within the wells turned yellow. After the addition of stop 
solution, the optical density (O.D.) was measured at the wavelength of 540 nm with a 
correction wavelength at 570 nm within 30 minutes. The detection range of the assay ranged 
from 7.8 to 500 pg/mL of RLN. 
 
4.11.5 Molecular and biochemical methods 
4.11.5.1 RNA isolation 
The total RNA was extracted using TRIzol® Reagent from both cells in culture and 
tissues [141, 144]. For the cell culture experiments, 6-well plates were used. Before 
harvesting, the medium was removed, and the cells were washed once with warm PBS. 
Quickly after removing the PBS, 1 mL of TRIzol® Reagent was added to each well. This 
step needed to be done as quickly as possible to minimize the changes in response to 
environmental stress occurring within the cells. The TRIzol® solution was pipetted up and 
down 4 to 5 times and collected into a 1.5 mL Eppendorf tube. After this step, the samples 
were snap frozen for further analysis, if necessary. Next, 200 µL of chloroform was added to 
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each of the samples. TRIzol® reagent and chloroform were mixed by vigorous shaking. 
When the phase separation could be seen, the samples were centrifuged for 15 minutes at 
14,000 rpm and 4° C. All steps that followed centrifugation were performed on ice. After 
centrifugation, 400 µL of the top aqueous phase was transferred into a new tube. Next 400 
µL of cold isopropanol and 1.5 µL of polyacryl carrier were added to the mixture. The 
samples were shaken vigorously again until all the components were mixed thoroughly. RNA 
was precipitated overnight in a -20° C freezer. After 16-24 hours of precipitation, the RNA 
was palleted at maximum speed for 15 minutes at 4° C. The supernatant was discarded, and 
the pallet was washed and centrifuged twice with 75% ethanol for 15 minutes at 14,000 rpm 
and 4° C. After the centrifugation step, the samples were allowed to air dry at room 
temperature for 5 to 10 minutes. 20 µL of ddH2O was added to dissolve the RNA pellet. 
After all the pellets had been dissolved, RNA concentration was measured using a 
NanoDrop2000.  
For tissue samples, approximately 15 mg of tissue was used per sample. The tissues 
were transferred into bead mill tubes containing 4 ceramic beads and 1 mL of TRIzol® 
Reagent and homogenized once at 6,000 rpm for 30 seconds. The homogenized solutions 
were centrifuged for 1 minute and transferred into a normal Eppendorf tube. RNA isolation 
techniques stated above were followed afterward.  
 
4.11.5.2 Reverse transcription 
RNA isolation and reverse transcription were done on the same day. After the RNA 
concentration measurement, 1 µg of total RNA was diluted with water to make the final 
volume of 15 µL. Next 4 µL of 5x reverse transcription buffer and 1 µL of reverse 
transcriptase were added to each reaction to make the final reaction volume of 20 µL. The 
reactions were performed with the following protocols (Table 10). 
Step Temperature Time Number of Cycles 
Annealing 25° C 5:00 1x 
Reverse transcription 42° C 30:00 1x 
Termination 85° C 5:00 1x 
Table 10: Reverse transcription program for RNA 
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After reverse transcription, the resulting cDNA was kept in a -20° C freezer. The 
cDNA was diluted 1:100 using DEPC treated water. Pending further analysis, the diluted 
cDNA was also frozen in the -20° C freezer.  
 
4.11.5.3 Quantitative real time PCR (qRT-PCR) 
iQ  YBR Green  upermix was used according to the manufacturer’s protocol. A final 
volume of 15 µL per reaction consisted of 7.5 µL iQ SYBR Green Supermix, 1 µL of 
forward and reverse primers mix (final concentration of 300 nM each), and 6.5 µL diluted 
cDNA (final concentration of 3.25 ng per reaction) was prepared [137, 141].  The qRT-PCR 
reaction was performed on a Bio-Rad CFX96 real-time PCR detection system with a protocol 
described in table 11. 
Step Temperature Time Number of Cycles 
Denaturation 95° C 3:00 1x 
Denaturation 
Annealing 
Elongation and reading 
95° C 
60° C 
72° C 
0:10 
0:10 
0:30 
40x 
 
Termination 95° C 0:10 1x 
Melting Curve 
65  95° C with 0.5° C 
increment 
0:05 60x 
Table 11: General qRT-PCR protocol 
 
The result of the qRT-PCR reaction was analyzed using CFX manager software. 
HPRT1 was used as a reference gene, and relative expression changes were calculated by 
applying the Ct method according to Livik and Schmittgen [145].  
 
4.11.5.4 Isolation of proteins 
Proteins were isolated using a 1% SDS buffer supplemented with protease inhibitor. 
After transfection experiments with HEK293T cell or transduction experiments with 
NRVCMs, the medium was removed from the plate, and the cells were washed once with 
warm PBS buffer. 100 µL of 1% SDS buffer was added to each well and the cells scratched 
off with cell scratcher. The lysed cells were sonicated 10 times to fragment the genomic 
DNA. The protein lysate was centrifuged for 1 minute and put on ice. Protein concentration 
measurement was performed using Bio-Rad Bradford protein assay. Different concentrations 
of BSA were used to generate a standard curve. First, in a separate tube, the protein lysate 
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was diluted 1:10 in 1% SDS buffer. For each reaction, 250 µL of buffer and 5 µL of buffer S 
were mixed together. The diluted lysate was added to the mixture and 2 mL of buffer B was 
added. The solution was incubated for 15 minutes away from light. After 15 minutes, the 
solution turned blue and measurement could be performed on an infrared spectrometry using 
a 750 nM wavelength. The optical density measurements from standard samples were used to 
plot a standard curve to generate a linear equation to calculate the amount of protein in each 
sample. The protein concentration of each sample was adjusted accordingly. For the in vitro 
experiment, 10 µg of protein was loaded per sample per lane, and for the in vivo experiment, 
20 µg of protein was loaded per sample per lane. After adjusting the concentration, the lysate 
was frozen in a -20° C freezer for later analysis. 
 
4.11.5.5 Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS page) 
The 4-20% SDS gels from Novex were purchased and used in all western blot 
experiments. First, the protein lysate was thawed on ice for half an hour. 5x loading buffer 
was added, and the lysate was incubated in the heating block at 95° C for 5 minutes. The 
lysate was centrifuged and loaded into SDS gel. Table 12 shows the amount of lysate that can 
be loaded onto different SDS gel types. 7 µL of standard ladder (Prestain Protein ladder) was 
also loaded onto the gel in order to determine the size of the protein of interest. The 
electrophoresis was performed for 1 hour 45 minutes at 100 V. After the first 20 minutes, the 
electrophoresis chamber was placed on ice in order to decrease the heat generated from the 
current.  
SDS gel type Loaded volume (per well) 
Maximum volume (per 
well) 
10 lanes gel 35 µL 50 µL 
12 lanes gel 30 µL 40 µL 
15 lanes gel 25 µL 30 µL 
Table 12: Sample volume for each type of SDS gel 
 
4.11.5.6 Western blot 
After electrophoresis, the SDS gel was electrophoretically transferred onto a PVDF 
membrane using the semi-dry blotting method [146, 147]. The blotting was performed in a 
cassette containing Whatman paper, PVDF membrane, SDS gel, and Whatman paper. The 
cassette was assembled in a blotting chamber from bottom to top. The membrane was 
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transferred at 15 V for 50 minutes. The blotted membrane was blocked in 0.2% I-block for 1 
hour. The I-block was discarded, and the blot incubated in respective antibodies overnight at 
4° C. The next morning, the antibodies were removed, and the membrane washed in TBS-T 
for 10 minutes 3 times. Then the blot was incubated in the respective secondary antibodies 
for 1 hour, and the blot was washed in TBS-T for 10 minutes, 3 times again. The signals from 
the blot were detected using an Odyssey infrared imager (LI-COR) detection system and the 
Images were processed using an Odyssey imaging software. Last, the blot was deactivated in 
methanol and allowed to air dry for 1 hour before being frozen in a -20° C freezer for long 
term storage. 
 
4.11.5.7 cAMP measurement 
cAMP measurement was performed using a cAMP Glo™ assay kit from Promega. 
The manufacture’s manual was followed. First, NRVCMs were seeded into a 96-well plate at 
20,000 cells per well (100 µL). The cells were transduced and stimulated accordingly. The 
medium was removed and 20 µL of test compounds in induction buffer (1x PBS 
supplemented with 500 µM IBMX and 100 µM Ro 20-1724) were added to the cells to 
stimulate cAMP production. After 15 minutes, 20 µL of lysis buffer was added to all wells. 
The cells were lysed at room temperature for 15 minutes. 40 µL of Detection buffer 
(Reaction buffer supplemented with Protein Kinase A) was added to all wells. Then the plate 
was mixed by shaking for 1 minute and incubated at room temperature for 20 minutes. 80 µL 
of Kinase Glo® Reagent was added to all wells and the plate was mixed by shaking for 1 
minute and incubated at room temperature for 10 minutes. The luminescence was read using 
a luminometer.  
 
4.11.5.8 Ca2+ transient measurement 
Intracellular Ca
2+
 transients were measured according to Yu et al. with modifications 
to fit available apparatus [148, 149]. NRVCMs were transduced with RXFP1 or LUC AAV 
vectors for 5 days. The medium was changed every two days. On the day of the experiment, 
the transfected NRVCMs were loaded with 1 µM Fura 2 AM in M199 medium at 37° C for 
15 minutes protected from light. After loading, the cells were washed with warm M199 
medium for 15 minutes at 37° C protected from light and connected to an electrode system on 
the table of an inverted fluorescence microscope (IX70 Olympus). The cells were electrically 
stimulated with 1 Hz bipolar. Using a monochromator, the Fura 2 AM loaded cells were 
excited at 380 nm. The alternative measurement of the bispectral emission (340 nm/380 nm) 
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was performed with the fluorescence microscope for a period of 5 minutes and the emission 
ratio was calculated with the software TILL vision. The data were exported to an online 
program written by Dr. Martin Bush. The following parameters were analyzed: a) the 
amplitude of the transient ([340 nm/ 380 nm]) and b) the diastolic Ca
2+
 ([340 nm/ 380 nm]). 
 
4.11.6 Statistical analysis 
GraphPad Prism software was used for statistical analysis. Data were expressed as 
means + SEM, unless otherwise indicated. An unpaired two-tailed  tudent’s t test was used 
when appropriate. A Mann-Whitney U test was used when the data was not normally 
distributed. To compare means among three or more independent groups exhibiting normal 
distribution, a one-way analysis of variance (ANOVA) was performed. A Tukey post-hoc test 
was applied when multiple comparisons were conducted. In case of non-normally distributed 
data, a Kruskal Wallis test was performed. A Dunn post-hoc test was applied when multiple 
comparisons were conducted. For all tests, p < 0.05 was accepted as statistically significant. 
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5 Results 
RLN and its cognate receptor, RXFP1, both play a vital role in cardiovascular adaptation 
during pregnancy. RLN naturally exerts its positive inotropic effects in the atria through PKA 
activation and cAMP accumulation. Increased secretion of RLN from cardiomyocytes during 
a decompensated HF event suggests that RLN and its receptor RXFP1 could be valuable 
targets for cardiac gene therapy.   
This study aimed to develop a novel regulatable gene therapy treatment for HF. The 
study was separated into three parts focusing on: 1) establishing a working in vitro model for 
proof of concept, 2) deciphering the mechanism behind the proposed treatment, and 3) testing 
the proposed treatment in an in vivo HF model. The first part of the study aimed to prove the 
feasibility of introducing functional foreign receptors into a cell, using a transduced primary 
cell model (NRVCMs). The second part of the study focused on deciphering the pathway 
responsible for RXFP1 activation, using the in vitro model established in part one of the 
study. Finally, the third part of the study focused on the safety and the efficacy of the gene 
therapy treatment in the in vivo HF model. A TAC operation was used to generate a 
hypertrophic HF in mice. AAV9 viral capsids containing Rat RXFP1 cDNA with 
CMV.MLC260 promoter were administered into TAC mice. Chronic administration of RLN 
was given to the animals using four weeks osmotic subcutaneous pumps. The effect of the 
treatment was evaluated relative to three control groups: TAC mice receiving control LUC 
virus with and without relaxin and TAC mice receiving RXFP1 virus without relaxin.  
  
5.1 Determination of RXFP1 expression in the heart 
According to the literature, RXFP1 expression in the ventricles is close to absent. This 
might contribute to the lack of RLN effects seen in the failed clinical trial [123]. To confirm 
this finding, RNA from different organs and parts of the heart was isolated and quantified. 
High RXFP1 mRNA expression in the heart could be detected compared to other organs 
(Figure 16 A). Figure 16 B shows a significant expression of RXFP1 mRNA in the atria 
compared to the ventricles. Therefore, the results of these experiments confirmed that the 
lack of RXFP1 expression led the lack of RLN response in the ventricles. 
 
 
 
 
Results 
 69 
 
Figure 16: RXFP1 expression profile.  
(A) Native RXFP1 mRNA expression in different organs (n=2-4) and (B) Native RXFP1 
mRNA expression in different parts of the heart (n=10). mRNA was isolated and quantified 
by qPCR. HPRT1 was used as a reference gene. *P < 0.05; **P < 0.01; ***P < 0.001. Error 
bars depict in SEM. 
 
5.2 In vitro experiments and proof of concept 
Due to the lack of RXFP1 expression in the left ventricle, an overexpression system 
was needed in order to yield the expression of RXFP1 in the targeted cells. The widely used 
adeno associated virus (AAV) vector and the cardiac specific MLC promoter were chosen as 
the systems of choice to deliver the gene of interest. 
 
5.2.1 Generating of AAV containing RXFP1 
Modified Rattus norvegicus RXFP1 cDNA sequence was synthesized and cloned into 
a pcDNA3.1 plasmid containing an N-terminal FLAG-TAG sequence using BamH I and Xho 
I restriction sites. The cassette was then sub-cloned into a single strand AAV genome 
plasmid, PSSV9, which contained CMV MLC260 promoter and SV40 poly A signal using 
Pst I and Xho I restriction sites. In silico analysis of the FLAG-TAG RXFP1 was performed 
and no interaction between the FLAG-TAG and other domains of the receptor was detected. 
Firefly LUC control virus was cloned using the same method and contained the same N-
terminal FLAG-TAG. 
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5.2.2 In vitro transfection of plasmids into the cell line 
A 
  
 
B 
 
 
 
 
 
 
 
 
 
 
Figure 17: RXFP1 expression in transfected 
HEK293T Cells. 
(A) Immunocytochemistry of RXFP1 
transfected HEK293T cells stained with FLAG 
antibody. None transfected cells and FLAG 
LUC transfected cells were used as negative 
and positive control respectively. Positive 
control cells were stained with red fluorescence 
secondary antibody and FLAG RXFP1 
transfected cells were stained with green 
fluorescence secondary antibody. (B) RXFP1 
mRNA expression in transfected HEK293 cells 
(n=4). HPRT1 was used as a reference gene for 
qPCR quantification. *P < 0.05; **P < 0.01; 
***P < 0.001. Error bars depict in SEM. 
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To ensure the expression of RXFP1 from the expression cassette, the plasmid was 
tested in THE HEK293T cell line. 3x10
5
 HEK293T cells were transfected with 1µg of 
pCDNA3.1 FLAG RXFP1 plasmid using PEI. After transfection, the cells were allowed to 
grow for 48 hours before being harvested for mRNA quantification and 
immunohistochemistry. Figure 17 A shows that RXFP1 protein expression could be detected 
with immunocytochemistry using FLAG-TAG staining antibody. After transfection 
HEK293T cells expressed 45-fold more RXFP1 mRNA compared to the negative controls. 
Therefore, RXFP1 expression from the cassette containing FLAG-TAG was detectable at 
both transcriptomic and proteomic levels. As a result, AAV virus production began. 
 
5.2.3 In vitro transduction of NRVCMs using AAV6 containing RXFP1 gene 
The FLAG RXFP1 cassette was sub-cloned from the pcDNA3.1 plasmid into a single 
strand AAV genome plasmid to generate RXFP1 carrying AAVs of serotypes 6 and 9 (AAV6 
and AAV9 respectively). Figure 18 A shows the construction of the plasmid. For in vitro 
experiments AAV6 was tested on NRVCMs to ensure sufficient transduction and detection of 
RXFP1. AAV6 RXFP1 at the MOI of 10,000 vg/cell was used to transduce 2x10
6
 NRVCMs 
for 5 days. mRNA was isolated, and qPCR was performed. 15-fold more RXFP1 mRNA 
expression could be seen in the RXFP1 transduced NRVCMs compared to none in the 
transduced control (Figure 18 B). Interestingly, compared to the native RXFP1 expression in 
the atria, the RXFP1 transduced NRVCMs showed 10-fold increase in RXFP1 mRNA 
expression as well (Figure 18 B). Unfortunately, detection at protein levels in NRVCMs was 
not possible due to unspecific background binding of the FLAG-TAG antibody. Detection of 
FLAG-TAG using the immunofluorescence technique yielded moderate success with the 
background signal still visible (Figure 18 C). Thus, artificial RXFP1 expression was able to 
be induced in NRVCMs using AAV6 RXFP1 viral transduction. 
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Figure 18: RXFP1 expression in transduced NRVCMs.  
(A) Diagram of RXFP1 cassette inserted into AAV viral plasmid. (B) RXFP1 mRNA 
expression in transduced NRVCMs (n=7-10). (C) RXFP1 expression in NRVCMs detected 
using nonpermeabilized immunofluorescence method stained with FLAG antibody. 
NRVCMs were transduced for 5 days. mRNA was isolated, and qPCR was performed. 
HPRT1 was used as a reference gene. *P < 0.05; **P < 0.01; ***P < 0.001. Error bars depict 
in SEM. 
C 
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5.2.4 Evaluating RXFP1 expression using cAMP levels as a readout 
 
Figure 19: cAMP accumulation after RXFP1 activation by RLN.  
Amount of cAMP measured in the RXFP1 and LUC transduced NRVCMs. NRVCMs were 
transduced with RXFP1 virus or LUC virus and treated with RLN. cAMP was measured 
using cAMP-Glo® kit. RXFP1 transduced NRVCMs treated with NaCl and LUC traduced 
NRVCMs treated with NaCl or RLN were used as control (n=5-20). *P < 0.05; **P < 0.01; 
***P < 0.001. Error bars depict in SEM. 
 
Naturally, ventricular cardiomyocytes do not express RXFP1 at the protein level. 
Therefore, a successful expression of RXFP1 at the transcriptional level does not necessarily 
result in functional RXFP1 receptors on the cell membrane. In order to test for the presence 
of functional receptors on the membrane, 2x10
4
 NRVCMs were transduced with AAV6 
RXFP1 virus at the MOI of 10,000 vg/cell for 5 days. Subsequently, 100 nM of RLN were 
used to stimulate the cells for 30 minutes. RXFP1 activation by its ligand is characterized by 
an increase in cAMP production within the cells. Therefore, cAMP accumulation was 
measured using a cAMP-Glo® kit. Compared to the control, a 5-fold increase in cAMP 
accumulation was detected in RXFP1 transduced cells treated with RLN (Figure 19). Thus, 
AAV mediated delivery of RXFP1results in ectopic expression of functional receptors as 
characterized by cAMP generation in response to receptor stimulation. 
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5.2.5 Establishing efficient dosage of AAV6 RXFP1 virus and RLN used for in vitro 
experiments 
To establish an efficient viral dosage used for in vitro experiments, NRVCMs were 
transduced with different MOIs of AAV6 RXFP1 virus, ranging from 5x10
3
 to 5x10
4
 vg/cell. 
After 5 days, the transduced cells were stimulated with 100 nM of RLN for 30 minutes. Then 
the amount of cAMP was measured and compared to the control. Figure 20 A shows that 
RXFP1 mRNA expression was increased in all transduced NRVCMs in a dose dependent 
manner with the highest amount of RXFP1 mRNA in samples treated with 5x10
4
 vg/cell. 
Figure 20 B shows that viral dosage of 5x10
3 
vg/cell did not alter cAMP production 
compared to the control treated cells. Other dosages, i.e. 1x10
4
, 2.5x10
4
, and 5x10
4
 vg/cell, 
did alter cAMP production significantly compared to the control (Figure 20 B). In detail, a 
1.5-fold increase in cAMP production was detected in the sample treated with 1x10
4
 vg/cell. 
Even though no significant increase in cAMP production between this dosage and the other 
higher dosages was observed, when compared to the control, this dosage of virus did produce 
a significant increase in RXFP1 mRNA expression and cAMP production. Thus, the viral 
dosage of 1x10
4
 vg/cell was chosen as it can significantly increase RXFP1 mRNA expression 
and activation of the RXFP1 dependent signaling.   
After establishing an efficient viral dosage for AAV6 RXFP1, we aimed to determine 
an efficient dosage of RLN stimulation. NRVCMs were transduced with AAV6 RXFP1 at a 
MOI of 1x10
4
 vg/cell. After 5 days, different dosages of RLN ranging from 1 pM to 100 nM 
were used to stimulate the cells for 30 minutes. After stimulation, cAMP was measured to 
detect the strength of RXFP1 activation from RLN stimulation. Figure 20 C shows that an 
increase in cAMP production can be seen with RLN dosage as low as 10 pM. Although 
increases in cAMP production could be seen in most test dosages, there was no difference 
detected between 1nM up to 100 nM RLN (Figure 20 C). However, in order to ascertain the 
likelihood of RXFP1 activation, the RLN dosage of 100 nM was chosen for further 
experiments. 
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Figure 20: Efficient dosage of RXFP1 virus and RLN in in vitro experiments. 
(A) RXFP1 mRNA expression in dosage dependent AAV transduction (n=3-4). Different 
dosages of RXFP1 were used to transduce NRVCMs. RXFP1 mRNA expression was 
analyzed using HPRT1 as a reference gene. (B) cAMP production in viral dose dependent 
manner (n=3). Different dosages of RXFP1 were used to transduce NRVCMs. 100 nM of 
RLN was used to stimulate the cells 30 minutes before cAMP production was measured. (C) 
cAMP production in RLN dose dependent manner (n=5). NRVCMs were transduced with 
RXFP1 virus and treated with different amounts of RLN for 30 minutes. cAMP production 
was measured. *P < 0.05; **P < 0.01; ***P < 0.001. Error bars depict in SEM. 
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5.2.6 Downstream signaling of RXFP1 and its potential positive inotropy effects 
 
Figure 21: PLB, AKT, ERK1/2 and MAPK phosphorylation in RXFP1 transduced NRVCMs 
treated with RLN. 
(A) P-PLB(S16)/PLB ratio in transduced NRVCMs treated with RLN (n=5), (B) P-
AKT(S478)/AKT ratio in transduced NRVCMs treated with RLN (n=5), (C) P-ERK1-
2/ERK1-2 ratio in transduced NRVCMs treated with RLN (n=5), and (D) P-MAPK/MAPK 
ratio in transduced NRVCMs treated with RLN (n=4) NRVCMs were transduced with 
RXFP1 and stimulated with 100 nM of RLN for 5 hours. Proteins were harvested and 
immunoblots were performed. GAPDH was used as an internal control for normalization. *P 
< 0.05; **P < 0.01; ***P < 0.001. Error bars depict in SEM. 
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After efficient dosages of AAV6 RXFP1 and RLN had been identified, further 
physiological changes from RXFP1 activation that could potentially lead to a positive 
inotropic response were investigated. RLN is known to increase the secondary messenger, 
cAMP, which could lead to physiological changes such as proliferation, differentiation, 
migration, etc within the cell. One downstream target of cAMP that could lead to positive 
inotropy is PKA. PKA is known to inactivate PLB by phosphorylation at serine 16 to 
increase SERCA2a activity, which in turn leads to a positive inotropic response from the 
cardiomyocytes. Therefore, P-PLB (S16) was used as a biochemical read out for positive 
inotropy.  
Using transduced NRVCMs, 100 nM of RLN was used to stimulate the cells for 5 
hours. The amount of P-PLB(S16) was calculated from immunoblots. A significant increase 
in P-PLB(S16) was detected in RXFP1 treated NRVCMs stimulated with RLN, compared to 
both viral treated controls and non-viral treated controls, with and without RLN stimulation 
(Figure 21 A). A 10-fold increase in P-PLB(S16) was consistently detected from all 
experiments. Interestingly, a trend toward an increase in P-PLB(S16) was also observed in a 
non-stimulated RXFP1 group. On the other hand, phosphorylation of AKT (S478), ERK1/2, 
and MAPKs was not increased (Figure 21 B - D).  Therefore, P-PLB(S16) was identified as a 
downstream biochemical effector protein target of RXFP1 activation that could potentially 
induce positive inotropy in an in vivo model.  
 
5.2.7 Induction of RXFP1 by RLN influences intracellular calcium handling 
Inactivation of PLB by phosphorylation at serine 16 is known to increase SERCA2a 
activity, which directly affects intracellular Ca
2+
 handling and positive inotropic effects. 
Therefore, the changes in intracellular Ca
2+
 current were investigated. The change in Ca
2+
 
transients amplitude was used as a readout for an increased contractility that could lead to 
positive inotropic effects. 
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Figure 22: Calcium transients measurement in RXFP1 transduced NRVCMs 
(A) Transients amplitude and representative Ca
2+
 transients and (B) Diastolic Ca
2+
 after 5 
minutes of NaCl, RLN, and ISO treatments (n=3-8). NRVCMs were transduced with RXFP1 
and LUC virus for 5 days. Ca
2+
 transients were measured with 1 Hz electrical stimulation. (C) 
RXFP1 mRNA expression. RXFP1 mRNA expression was analyzed using HPRT1 as a 
reference gene. For figure A only the first 4 groups were compared. *P < 0.05; **P < 0.01; 
***P < 0.001. Error bars depict in SEM. 
 
Using transduced NRVCMs loaded with 1 µM Fura 2 AM for 15 minutes and 
stimulated at 1 Hz, 100 nM of RLN was used to stimulate the cells for 5 minutes. 10 nM 
isoproterenol (ISO) treated NRVCMs were used as positive control. The changes in transients 
amplitude was measured. Figure 22 A shows a significant increase in amplitude in a group of 
NRVCMs that received both RXFP1 virus and RLN. Diastolic Ca
2+
 did not change in the 
analyzed groups except for the positive control (Figure 22 B). RXFP1, measured from 
isolated mRNA after the experiment, was significantly expressed in all groups of NRVCMs 
that received RXFP1 virus (Figure 22 C). It was therefore speculated that the significant 
increase in transients amplitude observed could lead to positive inotropic effects in an in vivo 
model. 
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5.3 RXFP1 pathway analysis in ventricular cardiomyocytes 
 
Figure 23: RXFP1-RLN signaling transduction in the presence of different inhibitors.  
Phosphorylation of PLB at serine 16 after RXFP1 virus treatment and recombinant RLN 
stimulation in the presence of different inhibitors (n=3-9). (A) H89 (5 µM), (B) melittin (1 
µM), (C) SQ22536 (90 µM), (D) gallein (75 µM), and (E) wortmannin (100 nM) 
respectively were added to transduced NRCVMs for 30 minutes, followed by RLN 
stimulation for 30 minutes. NRCVMs were harvested and P-PLB(S16)/PLB was quantified 
by immunoblot. Alpha actinin 1 (α-Actinin 1) immuno-detection was used as an internal 
control. *P < 0.05; **P < 0.01; ***P < 0.001. Error bars depict in SEM.  
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Data obtained from the in vitro experiments suggested that RXFP1 gene therapy with 
RLN treatment could improve multiple aspects of cardiac function. To decipher the pathway 
behind these improvements, a series of blocking experiments were performed using various 
chemicals that block different classical components of the GPCR signaling pathway. Changes 
in P-PLB(S16) was used as a readout for RXFP1 signaling induction.  
To determine which protein contributes to RXFP1-RLN signaling transduction, 
different proteins known to transduce classical GPCR signal were blocked. 5x10
5
 NRVCMs 
were transduced with RXFP1 virus. After five days, PKA, Gs, AC, G, and PI3k were 
inhibited individually within the cells using H89 (5 µM), melittin (1 µM), SQ22536 (90 µM), 
gallein (75 µM), and wortmannin (100 nM) respectively for 30 minutes, followed by RLN 
(100 nM) stimulation for 30 minutes, before being harvested for protein analysis. 
Immunoblots were performed. PLB and P-PLB(S16) were detected and quantified. -Actinin 
1 was used as an internal loading control. 
 
PKA: Figure 23 A shows that blocking of PKA with H89 markedly reduced downstream 
signaling of RXFP1 activation by RLN, as a notable decrease in P-PLB(S16) was detected. 
Thus, PKA could function as an important effector protein downstream of cAMP and up 
stream of PLB in the RXFP1 signaling pathway. 
 
 
Gs: Gs is essential for signaling initiation and signal transduction of RXFP1. Gs 
inhibition with melittin diminished RXFP1 activation by RLN, as P-PLB(S16) could not be 
detected (Figure 23 B). Therefore, blocking Gs significantly impairs RXFP1 downstream 
signaling cascade.  
 
AC: AC is a downstream protein that is activated by Gs. Figure 23 C shows, that blocking 
AC with SQ22536 slightly reduced downstream signaling of RXFP1 upon activation by 
RLN, resulting in a slight decrease in P-PLB(S16). Thus, AC might play a limited role in 
transducing the RXFP1 activation signal, by increasing the production of cAMP after RXFP1 
was activated by RLN. 
 
Results 
 81 
G: Inhibition of G with Gallein increased P-PLB(S16) after RXFP1 gene therapy and 
RLN stimulation (Figure 23 D). Thus, like many GPCRs, THE G protein might function as 
an inhibitor for the RXFP1 signaling transduction pathway. 
 
PI3K: Blocking of PI3K with wortmannin slightly reduced downstream signaling of RXFP1 
activation by RLN. A slight decrease in P-PLB(S16) was detected after wortmannin 
treatment and RLN stimulation (Figure 23 E). Thus, PI3K potentially has a limited function 
in RXFP1 signaling pathway.  
 
5.4 RXFP1 signaling vs -adrenergic signaling 
The RXFP1 signaling pathway shares many similarities with the -adrenergic (-AR) 
signaling pathway, as they produce similar effects. Data from in vitro and in vivo experiments 
suggest that RXFP1 activation is far less potent in the cells compared to -AR activation. To 
evaluate these observations, different aspects of RXFP1and -AR activation were compared. 
 
5.4.1 Positive inotropy from RXFP1 signaling and -AR signaling 
It is widely accepted that -AR activation leads to positive inotropy through different 
mechanisms such as phosphorylation of PLB, cytosolic calcium channels, and the ryanodine 
receptor (RyR). Likewise, RXFP1 activation potentially induces positive inotropy using a 
similar mechanism, but the signal strength between the two stimulations can vary. To test the 
differences in signal strength between RXFP1 activation and -AR activation, NRVCMs 
were isolated and transduced with RXFP1 or LUC control viruses. The transduced NRVCMs 
were treated with RLN (100 nM) or ISO (10 nM) for 30 minutes, before the cells were 
harvested. Immunoblots were performed to detect PLB and P-PLB(S16). GAPDH was used 
as an internal loading control. Results from the immunoblot suggested that RXFP1 activation 
produces less downstream signal compared to -AR activation (Figure 24). A significant 
increase in P-PLB(S16) was detected after -AR activation by ISO stimulation. On the other 
hand, RXFP1 activation by RLN stimulation only increased P-PLB(S16) to half of that 
observed in -AR activation (Figure 24). The signal intensity of the RLN treated group was 
significantly lower than the ISO treated group (approximately 55% lower). Thus, RLN 
stimulation only produces moderate downstream inotropic signaling compared to ISO 
stimulation. 
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Figure 24: RXFP1 activation and -adrenergic activation. 
Phosphorylation of PLB at serine 16 after RXFP1 viral treatment using various stimulations 
(n=3). Transduced NRCVMs were stimulated with NaCl, RLN (100 nM), or ISO (10 nM) for 
30 minutes. NRCVMs were harvested and P-PLB(S16)/PLB was quantified by immunoblot; 
GAPDH immuno-detection was used as an internal control. *P < 0.05; **P < 0.01; ***P < 
0.001. Error bars depict in SEM. 
 
5.4.2 Effects of RXFP1 activation vs -AR activation on PLB phosphorylation 
overtime.  
Prolonged activation of RXFP1 and -AR was examined in order to determine their 
effects over long term usage. NRVCMs were transduced for 5 days and they were stimulated 
with either 100 nM of RLN or 10 nM of ISO for 10 minutes, 30 minutes, 1, 3, 6, 12, and 24 
hours. The cells were harvested and immunoblots were performed to detect PLB, P-
PLB(S16) and P-PLB(T17). GAPDH was used as an internal loading control. Figure 25 
shows that RXFP1 activation led to a gradual increase in P-PLB(S16). A significant increase 
in P-PLB(S16) could be seen after 30 minutes onward, and at least 1 hour was needed in 
order for the signal to reach its plateau, which it then maintained throughout the experiment 
(Figure 25). P-PLB(T17) also increased, but at slower rate compared to P-PLB(S16). After 1 
hour, an increase in P-PLB(T17) became significant. 
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Figure 25: Effects of prolong RXFP1 and -AR activation. 
Phosphorylation of PLB at serine 16 and threonine 17 after prolong activation of RXFP1 and 
-AR (n=4). Transduced NRCVMs were stimulated with RLN (100 nM) or ISO (10 nM) for 
10 minutes, 30 minutes, 1 hour, 3 hours, 6 hours, 12 hours, and 24 hours. NRCVMs were 
harvested and P-PLB(S16)/PLB quantified by immunoblot; GAPDH immuno-detection was 
used as an internal control. *P < 0.05; **P < 0.01; ***P < 0.001; NaCl vs RLN / NaCl vs 
ISO. Error bars depict in SEM. 
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 On the other hand, -AR activation led to a sudden increase in both P-PLB(S16) and 
P-PLB(T17) (Figure 25). ISO stimulation produced a significant increase in P-PLB(S16) and 
P-PLB(T17) after only 10 minutes of stimulation. After 1 hour, the signal from ISO 
stimulation decreased and returned to an intermediate baseline, corresponding to the peak 
signal from RXFP1 activation. Thus, two conclusions could be drawn from these 
experiments: 1) long term RXFP1 activation is far less potent compared to -AR activation, 
and 2) RXPF1 relies on the gradual rise in P-PLB(S16) and P-PLB(T17), which is easier for 
the cells to cope with 
5.4.3 Role of CaMKII in RXFP1 activation comparing to -AR activation 
 
Figure 26: CaMKII activity after RXFP1 activation by RLN. 
Phosphorylation of PLB at serine 16 and threonine 17 after RXFP1 and -AR activation in 
the presence of CaMKII inhibitor (n=3). Transduced NRCVMs were stimulated with RLN 
(100 nM) or ISO (10 nM) for 30 minutes after blocking with KN92 and KN93 for 30 
minutes. NRCVMs were harvested. P-PLB(S16) and P-PLB(T17) were quantified by 
immunoblot. Alpha actinin 1 (α-Actinin 1) immuno-detection was used as an internal control.  
*P < 0.05; **P < 0.01; ***P < 0.001. Error bars depict in SEM. 
 
Since P-PLB(T17) was detected, CaMKII could play some role in RXFP1 activation. 
To determine whether CaMKII has any influence on signal transduction of RXFP1 by RLN, 
NRVCMs were transduced with RXFP1 virus and LUC control virus. After five days, 
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CaMKII was inhibited with KN93 (10 µM) for 30 minutes, followed by RLN (100 nM) 
stimulation for 30 minutes, before being harvested for protein analysis. Immunoblots were 
performed. PLB, P-PLB(S16), and P-PLB(T17) were detected and quantified. -Actinin 1 
was used as an internal loading control. RXFP1 activation by RLN showed that blocking of 
CaMKII using KN 93 did not produce any alteration in P-PLB(S16) and P-PLB(T17) (Figure 
26). Figure 26 shows that ISO induced -AR activation with CaMKII inhibition had no effect 
on P-PLB(S16) but did significantly decrease P-PLB(T17). Thus, these experiments 
demonstrate that RXFP1 activation does not influence CaMKII activity compared to -AR 
activation. 
 
5.5 RXFP1 activation is independent of -blocker 
 
Figure 27: RXFP1 activation in the presence of -blocker. 
Phosphorylation of PLB at serine 16 after RXFP1 and -AR activation in the presence of -
blocker (n=3). Transduced NRCVMs were stimulated with RLN (100 nM) or ISO (10 nM) 
for 30 minutes after blocking with -blocker (propranolol 1 µM) for 30 minutes. NRCVMs 
were harvested and P-PLB(S16)/PLB was quantified by immunoblot; GAPDH immuno-
detection was used as an internal control. *P < 0.05; **P < 0.01; ***P < 0.001. Error bars 
depict in SEM. 
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-blockers such as propranolol, atenolol, metoprolol, and etc. are a class of drug used 
as a first line treatment for HF.  -blockers block -AR from being hyperactively activated 
and delay the progression of HF. The influence of -blockers on RXFP1 activation was 
investigated in this experiment. Transduced NRVCMs were treated with -blockers, 
propranolol (1µM), for 30 minutes and stimulated with RLN or ISO for 30 minutes. The cells 
were harvested, and proteins were isolated. Immunoblots were performed. PLB and P-
PLB(S16) were detected and quantified. GAPDH was used as an internal loading control. 
Blocking of -AR did not influence RXFP1 activation in anyway. A similar amount of P-
PLB(S16) was detected with and without the presence of -blocker (Figure 27). Thus, the 
RXFP1 and -AR are different receptors, and blocking of -AR does not influence RXFP1 
activation and its downstream signal transduction.  
 
5.6 Similarity between human and rat RXFP1  
 
Figure 28: Comparison of RXFP1 between different species. 
Activation profile of RXFP1 from different species (n=3). NRCVMs were transduced with 
RXFP1 from different species for 5 days and stimulated with RLN (100 nM) for 5 hours. The 
cells were harvested and P-PLB(S16)/PLB was quantified by immunoblot; GAPDH immuno-
detection was used as an internal control. *P < 0.05; **P < 0.01; ***P < 0.001. Error bars 
depict in SEM. 
 
Many previous studies have focused on understanding rat RXFP1 rather than human 
RXFP1.  RXFP1 from both species are highly conserved, but yet different. To evaluate the 
difference between the two species, DNA and polypeptide chain sequences were compared. 
85% similarity in DNA, and 86% similarity in the polypeptide chain were detected, 
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respectively. Moreover, RXFP1 from both human and rat also exhibit identical response to 
RLN stimulation. Figure 28 shows that RLN stimulation led to a significant increase in P-
PLB(S16) detected in both the rat and human RXFP1 treated group. Thus, both rat and 
human RXFP1 behave comparably upon RLN stimulation. 
 
5.7 In vivo experiments 
In vitro detection of a significant increase in P-PLB(S16), after RXFP1 gene therapy 
with RLN stimulation, suggested that positive inotropy could be achieved in an HF animal 
model. After phosphorylation, PLB becomes inactive leading to SERCA2a activation 
followed by an increase in the amount of Ca
2+
 pumped into the SR. As a result, the 
cardiomyocytes undergo rapid repolarization that could contribute to positive inotropic 
response.   
 
5.7.1 Virus dose escalation study 
To successfully evaluate the proposed RXFP1 gene therapy treatment, an efficient in 
vivo viral transduction dose in a mouse model had to be established. 
 
5.7.1.1 Functional analysis and safety dosage 
 
Figure 29: Diagram of viral dose escalation experiments performed in vivo.  
The diagram shows the time line of the experiments performed in the viral dose escalation 
study. 
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Figure 30: RXFP1 expression with RLN treatment in in vivo model. 
(A) Baseline EF (B) Immediately after RLN EF (C) 3 hours after RLN EF, mice were 
administered with different concentrations of RXFP1 virus and allowed to express the 
transgene for 4 weeks. 1.35 µg/g recombinant RLN was administered intraperitoneally after a 
baseline echo was performed (n=5). Three echocardiography measurements were performed 
in order to assess the changes in cardiac function in the treated animals. (D) Baseline HR (E) 
baseline dp/dt min (F) baseline dp/dt max (G) After RLN stimulation HR (H) dp/dt min after 
RLN infusion (I) dp/dt max after RLN infusion, mice were given different concentrations of 
RXFP1 virus and allowed to express the transgene for 4 weeks. 1.35 µg/g recombinant RLN 
was administered intraperitoneally after baseline PV loop measurement (n=5). Error bars 
depict in SEM. 
 
To establish the most effective dosage of virus, 8 week old C57BL/6 mice were 
injected with different dosages of RXFP1 virus, ranging from 1x10
11
 to 3x10
12
 vg/animal. 
Each dosage group contained four animals. After 4 weeks, an acute dosage of RLN with a 
concentration of 1.35 µg/g was administered i.p. to each animal. The cardiac function was 
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measured by echocardiography, immediately after the injection, and three hours after the 
injection. Finally, the mice were catheterized through the left carotid artery, and left 
ventricular Pressure/Volume (PV) loop measurements were performed. Figure 29 shows the 
timeline of the interventions performed on the animals. 
The echocardiogram measurements of ejection fraction (EF) from the dose escalation 
animals showed no difference in any group at any time points (Figure 30 A-D). The EF from 
all RXFP1/RLN treated animals was similar to the LUC control/RLN treated animals (Figure 
30 A-C). The measurements from the echocardiogram suggest that treated animals do not 
experience any adverse effects from the RXFP1 gene therapy and RLN treatment. On the 
other hand, figure 30 F and I shows a trend toward an increase in dP/dt max observed before 
and after RLN treatment in RXFP1 group treated with a viral dose of 1x10
12
 vg/animal. The 
same trend toward a decrease dP/dt min could also be seen as well (Figure 30 E and H). 
Thus, the cardiac function results suggested that: 1) RXFP1 virus has no adverse effect on 
cardiac function in an in vivo model, and 2) RXFP1 gene therapy with RLN treatment does 
not enhance cardiac function in healthy animals. 
 
5.7.1.2 Molecular analysis and mRNA expression 
 
Figure 31: Molecular analysis of RXFP1 expression and RLN treatment in in vivo model. 
(A) RXPF1 mRNA expression in treated animals quantified by qPCR using HPRT1 as a 
reference gene. (B) Post-mortem cardiac P-PLB(S16)/PLB was quantified by immunoblot; 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) immuno-detection was used as an 
internal control (n=5). (C) RLN plasma concentration level (n = 5). *P < 0.05; **P < 0.01; 
***P < 0.001. Error bars depict in SEM. 
 
Once all the measurements were obtained, the mice organs were harvested for further 
analysis. qPCR was performed on harvested heart piece number 1. Immunoblots were 
performed on heart piece number 3 (see Figure 14), and plasma concentration levels of RLN 
were measured using an RLN ELISA kit. The results for qPCR showed a dose dependent 
expression pattern of the RXFP1 transgene (Figure 31 A). Significant RXPF1 expression 
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could be seen in samples treated with at least 1x10
12
 vg/animal, compared to the control. At 
protein level, a trend toward an increase in P-PLB(S16) could be seen in the groups that 
received 1x10
12
 vg/animal (Figure 31 B). Figure 31 C shows that similar RLN plasma 
concentration levels were detected in all animals that were administered RLN. Thus, the 
molecular evidence suggests that: 1) viral transduction could induce significant expression of 
RXFP1 in targeted cells, 2) a viral dosage of 1x10
12 
vg/animal with RLN treatment could 
produce significantly increased RXFP1 mRNA expression within the targeted cells, and 3) 
similar to in vitro model, a trend toward an increased P-PLB(S16) was detected, which could 
potentially lead to positive inotropic effects.  
 
5.7.2 Molecular effects of the AAV9 RXFP1 viral vector  
 
Figure 32: Volcano plot from RXFP1 treated animals. 
Volcano plot from RXFP1 treated animals. Microarray was performed on 3 animals with the 
highest expression of RXFP1 mRNA and 3 animals from LUC control group.  The results 
were plotted in a volcano plot in order to compare the differences in their gene expression 
profiles.  
 
To evaluate the safety of RXFP1 viral treatment at molecular level, a gene array was 
performed on 6 animals. Gene expression from 3 animals receiving RXFP1 virus without 
RLN treatment was compared to gene expression of 3 LUC control animals without RLN 
treatment. The expression profile was compiled, and a volcano plot was generated. RXFP1 
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was the only gene significantly up-regulated between the two groups (Figure 32). No 
alteration in expression pattern could be detected in other genes, as they resembled normal 
expression ranges. The data from viral dose escalation experiments strongly suggest that 
RXFP1 gene therapy does not have any off-target effects on normal cardiac function or alters 
gene expression patterns at the molecular level. The dosage of 1x10
12 
vg/animal was chosen 
for the study because it could significantly increase RXFP1 mRNA expression in the targeted 
cells.  
 
5.7.3 Relaxin dose escalation 
 
Figure 33: RLN plasma concentrations after chronic RLN administration.  
RLN plasma concentration after chronic administration of RLN. Healthy animals were 
implanted with osmotic pumps containing different concentrations of RLN. After 2 weeks 
plasma was collected and RLN plasma concentrations were measured. Error bars depict in 
SEM. 
 
To establish a suitable dosage of RLN, 8 weeks old C57BL/6 were implanted with 4 
weeks Alzet® osmotic pumps. Different dosages of RLN were filled into the pumps ranging 
from 0.35 µg/g/day to 1.35µg/g/day. The pumps were implanted subcutaneously into each 
animal. After 2 weeks, the amount of circulating RLN was measured using an RLN Elisa kit. 
The RLN plasma levels of the animals did exhibit a dose dependent pattern (Figure 33).  The 
two lowest dosages of RLN did not lead to a significant increase in RLN plasma 
concentrations. Figure 33 shows a significant increase in RLN plasma concentration in the 
group that received an RLN dose of 1.35 µg/g/day. The increase in RLN plasma 
concentrations observed was in line with previous studies regarding the effects of RLN 
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(unpublished data). Therefore, an RLN dosage of 1.35µg/g/day was chosen for future animal 
experiments, because it could reach RLN plasma levels previously shown to induce RXFP1 
activation.  
 
5.7.4 Establishment of a TAC-induced hypertrophic cardiomyopathy model 
 
Figure 34: Characterization of TAC-induced HF model. 
(A) Ejection Fraction (EF) (B) Fraction Shortening (FS) (C) Heart rate (HR) of sham and 
TAC animals over the period of 49 days (n=5-8). (D) Heart weight to body weight ratio was 
compared between sham and TAC animals (n=5-8). Post-mortem pathogenic cardiac 
remodeling genes expression (E) BNP (F) -MHC (G) ANP were quantified by qPCR with 
HPRT1 as a reference gene. Collagen formation genes were also quantified (H) Col1a1 (I) 
Col3a1 (n=5-8). *P < 0.05; **P < 0.01; ***P < 0.001. Error bars depict in SEM. 
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To generate a suitable and reproducible hypertrophic cardiomyopathy model, a 
transverse aortic constriction (TAC) operation was established. TAC operations were 
performed on 8 week old C57BL/6 mice in order to create a constriction on the aorta leading 
to an increased pressure in the left ventricle resulting in hypertrophic cardiomyopathy. A 
blunt 26-gauge needle and 8.0 prolene suture were used to ligate the aorta. Two knots were 
tied around the transverse aorta using the blunt 26-gauge needle as a guide. After the second 
knot the needle was promptly removed, and a constriction was created. A similar procedure 
was performed on the sham animals except the ligation of the aorta. The mice were followed 
for gradual deterioration in phenotype for 8 weeks after the operation using the 
echocardiogram. Figure 34 shows a significant decrease in all cardiac output parameters in 
TAC animals compared to sham animals. Deterioration in cardiac function could be observed 
from day 5 through completion. Post mortem analysis of heart weight to body weight ratio 
increased significantly in the 26-gauge TAC group (8.62  2.55 mg/g), compared to the sham 
group (Figure 34 D). Molecular data also showed an increase in pathological remodeling 
gene expression in all TAC animals (Figure 34 E - I). Thus, constriction using a 26-gauge 
needle could produce an HF phenotype with a marked decrease in cardiac function, 
accompanied by a significant increase in cardiac remodeling genes. 
5.7.5 RXFP1 mouse study 
 
Figure 35: In vivo study timeline with all interventions and measurements. 
TAC operations were performed on day 0, followed by virus transductions on the 7
th
 day, and 
pump implantations on the 28
th
 day. Echocardiography was performed at four different time 
points; two days before the TAC operation, 7 days after the operation, 28
 
days after the 
operation and 55 days after the operation.  
 
To prove the beneficial effects of RXFP1 gene therapy with RLN treatment, 8 week 
old C57BL/6 mice were TAC and sham operated. Figure 35 shows the complete timeline of 
the experiment. After one week the mice were randomized into groups and viruses were 
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administered. 3 weeks after viral transduction, the mice were implanted with either saline or 
RLN pumps. Cardiac functions of the mice were measured by echocardiography at weeks 0, 
1, 4, and 8 after the TAC operation (Figures 36). After 8 weeks, blood and tissue samples 
were collected, and RNA expression and protein expression were analyzed (Figure 37).  
 
5.7.5.1 Functional and pathophysiology analysis  
To detect the functional improvement from the RXFP1 gene therapy without bias, the 
echocardiography measurements were blindly analyzed for all animals.  
Functional improvement could be seen in all TAC animals that received RXFP1 gene 
therapy (Figure 36). Four weeks after the TAC operation, animals treated with RXFP1 gene 
therapy showed a slight improvement in EF and FS, compared to LUC control treated 
animals (Figure 36 A - B). Four weeks after pump implantation, a significant improvement in 
EF and FS were detected in a TAC group that received both RXFP1 gene therapy and RLN 
treatment. In addition to the functional improvements, a trend toward a decrease in LVIDd 
and LV mass was also detected (Figure 36 C - D). Post mortem examination of the lung and 
heart detected no different in HW:BW ratio in all TAC animals. However, a slight but not 
statistically significant improvement in LW:BW ratio was seen in a TAC group receiving 
both RXFP1 gene therapy and RLN treatment (Figure 36 E – F). Thus, RXFP1 gene therapy 
with chronic RLN administration improves cardiac function in a mouse post-TAC HF model.  
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Figure 36: Functional improvements after RXFP1 gene therapy treatment with RLN. 
(A) Ejection fraction (EF), (B) Fraction shortening (FS), (C) Left ventricular internal 
diameter (LVIDd), (D) Left ventricular mass (LV mass) of sham mice treated with and 
without recombinant RLN treatment and TAC mice treated with and without RXFP1 gene 
therapy and RLN (Sham + NaCl, Sham + RLN, TAC + LUC + NaCl, TAC + LUC + RLN, 
TAC + RXFP1 + NaCl and TAC + RXFP1 + RLN, n=8-9 in sham groups and n=14-15 in 
TAC groups). TAC animals were injected with 1x10
12
 vg/animal and implanted with either 
NaCl pumps or RLN pumps 4 weeks after TAC operation. (E) HW/BW, (F) LW/BW of 
tested mice measured post mortem. For (A) to (D) * FL NaCl vs. FR RLN, # FL RLN vs.FR 
RLN § FR NaCl vs. FR RLN, for (E) and (F) *P < 0.05; **P < 0.01; ***P < 0.001. Error 
bars depict in SEM. 
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5.7.5.2 Molecular analysis 
To evaluate the effectiveness of gene transfer, RXFP1 mRNA expression was 
measured in all samples by qPCR after the animals were sacrificed. A significant increase in 
RXFP1 mRNA expression was detected in animals that received RXFP1 gene therapy. Figure 
37 A shows that the animals expressed up to 1,500-fold more RXFP1 mRNA in the left 
ventricle compared to untreated animals and at least 500-fold more than native RXFP1 
expression in the atria.   
To detect improvement at the gene expression level, qPCR was performed, and 
expression of HF pathogenic remodeling markers, such as ANP, BNP, and -MHC, was 
evaluated. Figure 37 B - D shows a trend toward a decrease in ANP and -MHC in animals 
treated with RXFP1 gene therapy and RLN. This reduction in ANP and -MHC expression 
was accompanied by a significant decrease in BNP expression as well (Figure 37 C). 
Moreover, pro-collagen formation genes such as Col1a1, Col3a1 and Postn were also 
evaluated. A trend toward decreased Col1a1, Col3a1 and Postn expression were detected in 
both RXFP1 gene therapy groups regardless of RLN administration (Figure 37 E - G).  
To detect improvement at the protein level, protein expression analysis was 
performed and P-PLB(S16) was evaluated after the animals were sacrificed. Figure 37 H 
shows a trend toward increased PLB phosphorylation at serine 16 in the group treated with 
both RXFP1 gene therapy and RLN. A 5-fold increase in P-PLB(S16) was detected, which is 
in line with the in vitro data obtained from the prior experiments. Thus, the molecular 
analysis does match the functional analysis from in vivo animal experiments. 
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Figure 36: Molecular improvements in TAC animals after RXFP1 and RLN treatment.  
(A) RXFP1, (B) ANP, (C) BNP, (D) -MHC, (E) Col1a1, (F) Col3a1, (G) Postn mRNA 
expression in the ventricle detected 8 weeks after RXFP1 gene therapy treatment (n=8-15). 
mRNA expression was quantified using qPCR, with HPRT1 as a reference gene. (H) cardiac 
P-PLB(S16)/PLB quantification by immunoblot; GAPDH immune-detection was used as an 
internal control (n=8-15). *P < 0.05; **P < 0.01; ***P < 0.00. Error bars depict in SEM. 
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5.7.6 Relaxin plasma levels 
To determine whether circulating levels of RLN were sufficient to induce RXFP1 
activation in the treated animals, RLN plasma concentration was measured using an Elisa Kit. 
All animals that were treated with RLN showed a significant increase in RLN plasma 
concentration levels, compared to NaCl treated animals (Figure 38). The amount of RLN 
detected in the in vivo experiments was 3-fold lower than the amount or RLN used in the in 
vitro experiments. Nonetheless, this lower amount was still within range to induce RXFP1 
activation. Therefore, the obtained results confirm that the improved cardiac functions 
observed in TAC animals correlate with the beneficial effects of RXFP1 activation from RLN 
stimulation. 
 
Figure 38: RLN plasma concentrations. 
RLN plasma concentrations were determined using an Elisa kit (n=8-15). *P < 0.05; **P < 
0.01; ***P < 0.001. Error bars depict in SEM. 
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6 Discussion 
Heart failure is a leading cause of morbidity and mortality in the world [225]. HF is 
characterized by a dramatic increase in neuroendocrine activity, which raises the amount of 
circulating catecholamines, renin-angiotensin and mineralocorticoids, leading to long-term 
detrimental effects. One hallmark of HF is an over activation of the -AR pathway. This 
compensation mechanism helps the body cope with the worsening cardiac function but leads 
to an increase in mortality. On the other hand, over activation of -ARs will result in their 
desensitization upon exposure to catecholamines, which will worsen the symptoms of HF and 
eventually lead to patient decompensation.  
Physiologically, RLN is released during pregnancy in order to help the maternal 
cardiovascular system cope with the stress of pregnancy. However, a recent study by 
Dschietzig et al. has discovered that RLN is also released upon HF decompensation [46]. In 
addition, chronic administration of RLN increases global arterial compliance and thereby 
reduces systemic vascular resistance and ventricular afterload leading to an increase in 
cardiac output [150]. These changes in the vascular system resulting from RLN secretion 
help the body recover from the decompensated stage. Other beneficial effects of RLN include 
angiogenesis, anti-inflammatory, and anti-fibrotic properties [94, 223]. Furthermore, in 2011, 
Dschietzig et al. discovered that RLN increases the twitch tension of isolated adult atrial 
cardiomyocytes regardless of HF status [98]. However, no change in ventricular cells was 
detected.  
Taking into consideration the numerous benefits that RLN has on the cardiovascular 
system, an RLN clinical trial was conducted. The result of a phase I trial concluded that RLN 
treatment was beneficial for acute HF treatment [151, 152]. However, a larger study cohort 
failed to meet a defined endpoint, leading to its termination [132]. The failure of RLN 
treatment was primarily attributed to the lack of RXFP1 expression in the left ventricle, 
which is essential for the beneficial effects of RLN [55, 81]. Likewise, endogenous secretion 
of RLN during HF can increase the likelihood of beneficial effects being observed after 
RXFP1 gene therapy [131].  
Therefore, the aim of this study was to investigate whether the ectopic expression of 
RXFP1 combined with RLN treatment can be developed into a gene therapy treatment for HF 
in an in vivo HF model. Although overexpression of RXFP1 in the heart has been 
investigated [153], coupling the overexpressed receptor to its ligand, RLN, has never been 
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studied before. This study would represent the first attempt at developing a gene therapeutic 
approach for the treatment of HF that is controllable by an exogenous RLN application. 
 
6.1 Effects of RXFP1 overexpression in an in vitro model 
6.1.1 Validation of RXFP1 expression  
In order to study RXFP1’s intracellular function, an effective overexpression and 
detection system was needed. To aid RXFP1 detection at the protein level, a FLAG-TAG was 
added to the RXFP1 construct used in this study. In silico analysis had demonstrated minimal 
structural interaction between the FLAG-TAG and RXFP1 that could interfere with protein 
folding and ligand binding sites. Native RXFP1 expression was detected in NRACMs, but 
not NRVCMs. Previous studies of an adult murine heart showed similar results. The same 
expression pattern was also seen in human hearts [154, 155]. Native RXFP1 expression in 
other organs was observed to be much lower compared to the expression in the atria of the 
heart. Mouse RXFP1 expression is only detectable in the heart and brain, which is different 
from human RXFP1 expression that could be detected in many organs. Protein expression 
database (Protein Atlas) also suggests that RXFP1 is only expressed at a very low level in 
most organs, which could be impossible to detect by qPCR.  Using an AAV viral system, 
NRVCMs were transduced with an RXFP1 carrying virus, which resulted in overexpression 
of RXFP1 at mRNA level. Compared to the native expression of RXFP1 in the atria, viral 
overexpression significantly increased the amount of RXFP1 mRNA by 10-fold. Moreover, 
the amount of RXFP1 mRNA observed in the overexpression experiments was also much 
higher compared to native RXFP1 expression in all organs that are known to express it. 
Although RXFP1 was tagged with a specific epitope, detection at the protein level was still a 
challenge. Immunofluorescence images did not lead to a clear conclusion regarding the 
expression of RXFP1, due to unspecific interactions between the FLAG-TAG antibody and 
other membrane proteins. Furthermore, interference from post-translational modifications 
could lead to a lack of interaction between the FLAG-TAG antibody and the targeted epitope, 
resulting in a decrease in signal strength and an increase in background noise [156]. Finally, 
RXFP1 expression on transduced cardiomyocytes was detected with moderate success using 
an optimized immunofluorescence stain without permeabilization. This method still produced 
some background noises, but cardiomyocytes with high RXFP1 expression could still be 
distinguished. It is known, that GPCRs, such as -adrenergic receptor, are challenging to 
detect at the protein level due to their high molecular weight and post-translational 
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modifications [157]. Hence, this limitation in protein detection is acceptable for this type of 
study, because it is considered to be a characteristic of the family of GPCR proteins. 
 
6.1.2 Safety of RXFP1 overexpression and positive inotropic potential from RXFP1-
RLN signaling  
In addition to developing a method to overexpress RXFP1 in targeted cells, the 
receptor function was also assessed. Upon recombinant RLN stimulation in NRVCMs, an 
increase in cAMP production was observed in a dose dependent manner. A viral MOI as low 
as 5,000 vg/cells could induce a cAMP response in the transduced cells. Increasing dosages 
of virus led to further increase in cAMP production, until a decline was detected at a viral 
MOI of 50,000 vg/cells. This decline was attributed to stress from unfolded protein 
production [158]. Proteins produced in the cell need to undergo post translational processing 
in the ER before being transported to the correct compartment [158, 159]. Delicate cellular 
mechanisms for monitoring ER environment are essential for cells to effectively produce and 
secrete mature proteins [160]. Accumulation of unfolded proteins from overproduction leads 
to a disruption in this monitoring mechanism, which could result in ER stress induced cell 
death. This mechanism could explain why at high viral MOI, there is less cAMP production 
within the transduced cells.  
On the other hand, when different dosages of RLN were used for stimulation, an 
increase in cAMP production was detected, with a dosage as low as 10 pM. Normally a 
ligand concentration threshold has to be met in order to activate the receptor [47]. However, 
at very low RLN concentrations (sub pM through pM range), RXFP1 utilizes a preassembled 
signalosome to scaffold to AC2 via AKAP79 and thereby induces cAMP accumulation [47, 
161]. The cAMP produced is tightly regulated by the activity of PKA-activated PDE4D3 
scaffolded to the receptor C-terminus by -arrestin 2 [47]. A higher dosage of RLN (nM 
range) further increases cAMP production through the classical RXFP1-RLN signaling 
pathway, utilizing Gs, PI3K and AC5 [68, 76, 78, 162]. The production of cAMP reached its 
plateau at the RLN concentration of 10 nM.   
Classical downstream signaling proteins in the RXFP1-RLN signaling pathway 
affected by an increase in cAMP production are: MAPKs [163], ERK1/2 [164, 165], and 
AKT [165-167]. However, none of these proteins were affected in the transduced ventricular 
cardiomyocytes in our study, since no difference in MAPKs, ERK1/2 and AKT 
phosphorylation was observed in NRVCMs receiving both RXFP1 virus and RLN 
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stimulation.  On the other hand, when transduced NRVCMs were stimulated with RLN, an 
increase in P-PLB(S16) was detected. Many previous studies have linked phosphorylation of 
phospholamban to SERCA2a activation, leading to an increase in SR calcium uptake, 
resulting in positive inotropy [168-171]. Furthermore, a significant increase in Ca
2+
 transients 
amplitude was detected in NRVCMs treated with RXFP1 gene therapy and recombinant RLN 
stimulation. The observed higher amount of intracellular Ca
2+
 could be the result of 
prolonged action potential (AP), which increases the amount of Ca
2+
 entering the cell through 
both L-type and T-type Ca
2+
 channels [57, 62, 172]. Interestingly, the observed increase in 
cAMP, P-PLB(S16) and Ca
2+
 transient amplitude could explain what Dschietzig et al. 
observed when RLN stimulation resulted in an increase in twitch tension in atrial 
cardiomyocytes [98]. Thus, the increase in Ca
2+
 from prolonged AP coupled with a higher 
activity of SERCA2a through phospholamban phosphorylation could link molecular changes 
to stronger contractility observed in an in vivo model seen later [173]. 
In summary, these experiments prove that viral transduction could lead to a 
significant increase in RXFP1 expression on the targeted cells. Furthermore, the expressed 
receptors are fully functional and signal through the classical RXPF1-RLN pathway utilizing 
cAMP. Increase in cAMP activates PKA, which phosphorylates phospholamban at serine 16 
and subsequently increases the activity of SERCA2a. On the other hand, RXFP1 stimulation 
by RLN also increases the Ca
2+
 influx through prolonged AP. Thus, this chain of events 
suggests potential positive inotropic effects that could be derived from RXFP-RLN signaling 
pathway in the transduced ventricular cardiomyocytes.  
 
6.2 Evaluation of RXFP1 gene therapy treatment in vivo  
6.2.1 Establishing effective dosage of RXFP1 and RLN in vivo 
A major milestone in the advancement of gene therapy was the development of tissue 
specific viral capsids that were reliable and precise enough to deliver a onetime gene 
alteration treatment to a targeted cell type. Attempting to develop a regulatable gene therapy 
treatment by combining a receptor and its agonist has never been done before and therefore 
presented many challenges.  
As a first step in this study, we aimed to determine the effective dosage of RXFP1 
virus in healthy animals. Different dosages of RXFP1 virus in the range of 3x10
11
 to 1x10
12
 
vg/animal were given to healthy animals by systemic injection through the tail vein. Systemic 
injection, as opposed to other routes of administration, such as direct injection, has a lower 
Discussion 
 103 
risk and a higher translational potential in terms of treatment [174, 175].  Significant increase 
in RXFP1 mRNA expression was detected in the left ventricle at the 1x10
12
 vg/animal dose. 
In line with previous studies, viral genome concentration of 1x10
12
 lead to a significant 
increase in the expression of the gene of interest in the host animals [176-178]. Compared to 
native RXFP1 expression in the un-transduced atrial cells, a10-fold increase was detected in 
the transduced ventricles. Therefore, it can be assumed that 1x10
12
 vg/animal is an optimal 
concentration of virus that could lead to the required RXFP1 expression needed for RLN 
signal transduction. 
Many studies have detected high variation in RLN plasma concentration levels when 
RLN was administered intraperitoneally or subcutaneously, due to different absorption rates 
between animals. Alongside i.p. and s.c. routes, intravenous (i.v.) administration of RLN 
might lead to a higher level of RLN presented systemically; however, rapid metabolization of 
the peptide by the body would result in quick excretion without maintaining an effective 
plasma concentration [179, 180]. Hence, implantation of osmotic pumps remains the only 
effective method for a chronic administration of RLN. Different dosages of recombinant 
RLN were administered to healthy animals via osmotic pumps for 28 days.  Stable plasma 
concentration levels were reached after 14 days. In our study, recombinant RLN dosage of 
1.35 µg/g/day led to RLN plasma concentration levels of 38.66  12.27 ng/mL. This 
concentration is 3-fold less than what was used in the in vitro experiments, but it was still 
calculated to be ~30 nM of RLN, which is capable of inducing RXFP1 activity. In vitro 
experiments showed that significant induction of RXFP1 activity occurred when RLN 
concentration is in excess of 10 pM. In addition, this evidence suggests that the amount of 
RLN could be adjusted to induce RXFP1 activity that is suitable for individual needs. 
Considering the higher metabolism of rodents, the effective dosage of RLN established here 
was expected to be higher than the 30 µg/kg/day dosage, which is effective in humans [46]. 
Even higher dosages were not tested due to technical limitations as this was the highest 
concentration of commercially available RLN. On the other hand, lower concentrations of 
RLN were tested but no used, since lower concentrations: 1) could not produce effective 
plasma concentration and 2) could introduce unnecessary error from dilution. Thus, RLN 
dosage of 1.35 µg/g/day was determined as most likely to produce measurable effects from 
RXFP1 activation that are beneficial for cardiac function.  
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6.2.2 Effects of RXFP1 overexpression and RLN treatment in healthy animal 
In this study, AAV mediated overexpression of RXFP1 in healthy animals did not 
produce any observable side effects during a one-month evaluation period. The treated 
animals did not exhibit any pathological phenotype neither physically nor molecularly. 
Furthermore, a microarray mRNA expression analysis detected similar mRNA expression 
profiles between RXFP1-transduced and LUC control transduced animals, with a significant 
increase in RXFP1 mRNA expression being the only significant difference detected. As such, 
expression of RXFP1 in healthy animals does not affect any functional or molecular 
parameters. 
The effects of RXFP1 activation by RLN depend largely on the cell type being 
stimulated. So far, these effects have been well studied in cells that naturally express RXFP1 
or cell lines generated specifically for the study of RXFP1 activation [49]. Nonetheless, all 
these models have never addressed artificial in vitro and in vivo RXFP1 expression and 
activation in a cell type that does not express it naturally. In our study, animals with ectopic 
ventricular RXFP1 expression were functionally assessed before and after recombinant RLN 
treatment. The results showed no functional change in HR, EF and FS before or after RLN 
administration. Additional evaluation using a more sensitive PV loop measurement detected a 
slight trend toward a rise in myocardial contractility (dP/dt max) in animals receiving the 
highest dosage of RXFP1 gene therapy regardless of RLN stimulation when compared to the 
LUC control animal. This trend could be interpreted as an effect of RXFP1 overexpression 
alone rather than the combined effect of RXFP1 with RLN induction.  
Many studies demonstrated that in vitro activation of RXFP1 in the atria 
cardiomyocytes lead to positive inotropic and chronotropic responses [55, 181, 182], but 
these effects might not be detectable in healthy animals. It is important to note that RXFP1 
was expressed in healthy animals, which might have blunted the beneficial effects of the 
concurrent RLN treatment, as the maximum cardiac function is already reached in these 
animals. On the other hand, it could be theorized that the downstream components of RXPF1 
might not be readily available in heathy tissues which could lead to a lack of response as 
well. This component could be Gαi, which is known to be upregulated in HF [26]. In 
addition, it is also well known that Gαi is essential for second surge of cAMP and PKA 
activation in the RXFP1-RLN signaling pathway, which could lead to an increase in PLB 
phosphorylation and calcium influx [78-80, 183]. In summary, these experiments suggest 
that: 1) RXFP1 gene therapy with RLN treatment does not have detrimental effects in an 
animal model, 2) RXFP1 expression does not lead to any increased in cardiac output in 
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healthy animals, 3) significant increase in RXFP1 mRNA expression could be achieved with 
viral dosage of 1x10
12
 vg/animal.   
 
6.2.3 Generation of a relevant HF model 
Several mouse models exist for the study of HF [184]. These models start with 
various types of cardiac remodeling through the introduction of different kinds of stress. A 
common end point of all cardiac remodeling is HF [11, 185]. In this study, HF was a result of 
TAC surgery, which causes pressure overload in the left ventricle due to the constriction of 
the aorta [142, 143]. This pressure overload leads to cardiac hypertrophy similar to what is 
observed in patients with chronic hypertension and aortic stenosis[186, 187]. Eventually the 
systolic pumping function of the heart will start to fail as a result of left ventricular 
hypertrophy leading to HF. Previous studies using this model have shown that HF develops 
anywhere from 6 to 8 weeks after TAC depending on the response to the strain of mouse used 
[188, 189].  
Assessment of cardiac function and post mortem analysis of molecular alterations in 
ANP, BNP, -MHC, Col1a1, Col3a1, and Postn, all hallmarks of HF, were used to ensure 
that the generated phenotype resembles what has been described in THE literature [190, 191]. 
Significant decrease in cardiac function such as EF and FS accompanied by significant 
upregulation of ANP, BNP, -MHC, Col1a1, Col3a1, and Postn were indeed detected in the 
TAC animals in this study, 8 weeks after TAC. In line with previous studies, the HF 
phenotype was accompanied by significant up-regulation of pathological cardiac remodeling 
genes [190, 192, 193]. Moreover, up-regulation in collagen formation genes led to a 
significant increase in heart-weight to body-weight ratio, observed in all TAC animals 
evaluated. In summary, the TAC operation used in this study was able to generate a HF 
phenotype that have been described before by numerus reports. 
 
6.3 Potentially controllable gene therapy rescues HF in the TAC model 
6.3.1 Expression of RXFP1 alone is moderately beneficial for HF 
Many studies have described the beneficial effects of RXFP1 activation by RLN in 
different cell types such as fibroblasts, endothelia, and atrial cells both in vitro and in vivo 
[55, 194-196]. However, none has described the beneficial effects of RXFP1 expression 
alone. In this study, the beneficial effects of RXFP1 expression in the ventricular 
cardiomyocytes was confirmed. RXFP1 expression slightly improved cardiac function in the 
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TAC animals. However, these increases in EF and FS did not lead to an overall functional 
improvement in HF. Similar improvement can be seen at the molecular level, as a decrease in 
ANP, BNP, -MHC, Col1a1, Col3a1, and Postn expression was detected. These 
improvements might be the result of RXFP1 activation by endogenous RLN. Previous studies 
have discovered that male reproductive organs secrete a small amount of RLN which can 
enter circulation and lead to activation of RXFP1 [197-199]. Moreover, Dschietzig et al. have 
discovered that RLN is also secreted by the cardiomyocytes themselves during HF. It is 
therefore tempting to speculate that the moderately beneficial effects from LV-specific 
RXFP1 expression are (at least in part) due to the activity of endogenous RLN. Even though 
only a small amount of RLN is produced, it might be still enough to induce RXFP1 activation 
and improve the contractility of the heart. 
 
6.3.2 RXFP1 gene therapy with RLN treatment rescues HF 
The beneficial effects of RXFP1 gene therapy combined with RLN treatment were 
validated in an experimental HF model, to confirm the potential inotropic property shown 
earlier in NRVCMs. Thus far, RLN has been shown to only induce positive inotropy in the 
atria, but not in the ventricle, due to lack of ventricular RXFP1 expression [55, 62, 81]. 
Consequently, we chose to use a cardiac targeted system (cardiotropic AAV-based viral 
vector and cardiac enriched promoter) to enrich RXFP1 expression specifically in the heart. 
With RXFP1 gene therapy, RXFP1 is readily available in the ventricle to interact with RLN. 
First, RXFP1 activation by RLN induced positive inotropy, as significant increase in EF and 
FS were detected after RLN treatment, compared to that of the control animals. These 
improvements in cardiac function were accompanied by a rise in PLB phosphorylation at 
Serine 16. Increase in cardiac contractility has been linked to inactivation of PLB through 
phosphorylation [200, 201]. PLB binds to and inhibits SERCA2a. Phosporylation of PLB 
results in the release of SERCA2a binding and thereupon its disinhibition. SERCA2 
activation in turn leads to more efficient Ca
2+
 sequestration to SR and a lusitropic effect, or 
higher muscle relaxation, which could explain the observed improvement in cardiac function 
[224].  In addition to improvement in contractility, a trend towards a decrease in heart- 
weight to body-weight and lung-weight to body-weight were detected as well. These trends 
suggest that the treated animals experienced less hypertrophy and less apoptosis, resulting in 
a milder form of HF compared to the control treated animals.  
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Several underlying mechanisms have been proposed to explain the cardioprotective 
effects of RLN. Samuel et al. demonstrated that RLN has anti-fibrotic and anti-hypertrophic 
properties, which are mediated by cardiac fibroblasts [154, 202]. Lekgabe et al. further 
demonstrated that long-term administration of RLN lowers collagen content in the left 
ventricle, reverses cardiac fibrosis, and ameliorates left ventricular dysfunction [203]. 
Furthermore, Moore et al. proposed that RLN might exert its anti-hypertrophic property by 
changing the secretion profile of cardiac fibroblasts to suppress hypertrophy in 
cardiomyocytes [204]. Xu et al. and Chan et al. demonstrated that effects of RLN on the 
vascular system could protect against hypertension-induced cardiac dysfunction and reverse 
hypertension-associated fibrosis [205, 206]. Additionally, Nistri et al. theorized that RLN 
could induce maturation of myocardial progenitor cells through expression of cardiac specific 
structural genes at both mRNA and protein level [60]. All in all, the cardioprotective effects 
on both cardiomyocytes and vascular cell could result in an improved cardiac cell survival, 
which in turn leads to the preserved cardiac function observed in this experiment. 
The molecular data were in line with what was observed phenotypically and 
functionally. First, several hypertrophic markers were analyzed. Classically BNP mRNA 
expression correlated to the severity of HF[207]. Since the phenotype of heart failure is less 
severe after RXFP1 gene therapy and RLN treatment, a significant decrease in BNP was 
detected. Furthermore, a trend toward a decrease in ANP and -MHC was also observed in 
this treatment group which is in agreement with the phenotype seen. Second, a molecular 
signature of collagen depositions was evaluated, as this is a very important mechanism in 
cardiac remodeling and a hallmark of HF development [208]. Its attenuation will result in an 
improvement in the HF phenotype. Indeed, expression of collagen production related genes, 
such as Col1a1, Col3a1, and Postn, was blunted in RXFP1 gene therapy groups regardless of 
RLN treatment. Thus, cardiac remodeling could be attenuated in our mouse model by RXFP1 
gene therapy. Moreover, HF could be rescued by a combined treatment of RXFP1 gene 
therapy and RLN stimulation.  
Apart from the RXFP1-RLN effects in the ventricle, other pleotropic effects of RLN 
could have also led to an improvement in the HF phenotype. RLN is also known for its 
vasodilative and angiogenic properties [195, 209]. Increase in RLN concentration could have 
activated the NO/cGMP pathway in vascular smooth muscle and coronary artery 
endothelium, leading to an increased production of NO, and ultimately resulting in 
vasodilatory responses [57, 209, 210]. Long-term exposure to RLN could have induced 
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production of VEGF and b-FGF in endometrial cells leading to angiogenesis at injured sites 
and promote healing [211, 212].  These pleotropic effects of RLN could have also 
contributed to the improved HF phenotype observed in RXFP1 treated animals. These 
potential effects go beyond the scope of this thesis and should be evaluated in future studies. 
In conclusion, the proposed treatment is based on the interaction of two components 
that need each other to effectively treat HF. Viral gene transfer of RXFP1 leads to stable 
expression of the receptor (approximately 500 folds more than native RXFP1 expression in 
the atria), which was shown to be safe. The second arm of the treatment, RLN, is a peptide, 
whose administration can be spatiotemporally controlled. Different amounts of RLN could 
control the beneficial effects of RXFP1-RLN interaction, as demonstrated in this study. 
Based on this observation, the effects of the combined treatment could be tightly controlled 
and fine-tuned by adjusting the dose of exogenous RLN. Thus, this study demonstrates for 
the first time a potentially controllable gene therapy treatment utilizing a membrane protein 
and its ligand.  
 
6.4 Elucidation of RXFP1-RLN signaling pathway in ventricular cardiomyo-
cytes 
As described before, RXPF1 activation by RLN induces an increased production of 
second messengers such as cAMP, cGMP and NO within the cell [213]. As a result, mRNA 
expression and protein phosphorylation patterns are altered depending on the cell type being 
stimulated. RLN has been extensively studied in endothelial cells and fibroblasts, as the 
current widely believed hypothesis, is that RLN has mainly vasodilatory, anti-fibrotic and 
angiogenic properties [57, 195, 202, 210-212, 214]. On the other hand, the inotropic effects 
of RLN discovered in atrial cardiomyocytes by Dschietzig et al. never gained momentum for 
further investigation. 
 In this study, the inotropic pathway of RXFP1 activation by RLN was elucidated in 
vitro. Different signaling proteins of the RXFP1-RLN signaling pathway were inhibited in 
RXFP1 transduced NRVCMs before RLN stimulation. Change in P-PLB(S16) levels was 
used as an endpoint in this study in order to assess which protein played an important role in 
the signaling pathway.  
Gs: When the Gs subunit of the heterotrimeric g-protein was inhibited, RXFP1 activation 
by RLN could not produce any detectable P-PLB(S16), compared to control cells, where P-
PLB(S16) was abundant. Gs is the component that initiates a signaling cascades in many 
GPCRs [215]. However, some GPCRs might signal through other subunits of heterotrimeric 
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G-protein [78, 216]. Many studies, including this one, have shown that RLN signals through 
Gs in order to increase cAMP production, which leads to further responses from the cell [68, 
88]. When compared to strong inotropic agents, such as ISO, RXFP1 activation produces a 
noticeably lower cAMP and P-PLB signal. However, this could be attributed to a loose 
coupling between RXFP1 and Gs subunit [77]. To conclude, the Gs subunit of the 
heterotrimeric G-protein is essential for RXFP1-RLN signaling pathway, and it is needed for 
all downstream signaling.   
AC: When AC was inhibited, RXFP1 activation from RLN stimulation resulted in a 
moderate reduction in P-PLB(S16) signal (20% lower than the original signal). As described 
before, in different cell types other than cardiomyocytes, Gs stimulates AC in order to 
increase cAMP production after RXFP1 activation. This increase in secondary messenger 
production leads to alterations in gene expression and protein phosphorylation. However, in 
this study, RLN seems to signal through other specific ACs presented in cardiomyocytes. 
Current understanding of RXFP1 signaling specifies various isoforms of AC as being 
responsible for cAMP production, depending on the type of cell being stimulated [217, 218]. 
However, most of these studies were done in fibroblast or endothelia which have different 
AC expression profiles than cardiomyocytes. There are two primary isoforms of AC in 
cardiomyocytes, AC5 and AC6 [219-221]. AC5 is primarily expressed in adult 
cardiomyocytes and AC6 is primarily expressed in neonatal cardiomyocytes [222]. Other 
isoforms of AC are also present in the heart, but in much lower quantities [223, 224]. This 
difference in expression profile can explain why the expected decrease in P-PLB(S16) was 
dampened. In addition, the AC inhibitor displays different affinities toward different isoforms 
of AC [219], resulting in an insufficient blockage of the relevant isoforms. In this experiment, 
increasing the amount of inhibitor to block the dominant isoforms was not possible, without 
having a detrimental effect on the cells. Thus, the moderate inhibition of P-PLB(S16) could 
be attributed to the insufficient inhibition of the AC isoform (e.g. AC5 and AC6), through 
which RLN induces cAMP production and positive inotropic response.   
PKA: In this study, inhibition of PKA led to a substantial decrease in P-PLB(S16) levels. 
PKA is a signaling protein downstream of cAMP [225].  Activation of PKA by cAMP lead to 
phosphorylation of many proteins and ion channels [225, 226]. PKA is known to directly 
phosphorylate PLB at serine 16, thus disinhibiting/activating SERCA2a activity [200, 227]. 
SERCA2a is a Ca
2+
-ATPase, which transports Ca
2+
 from the cytosol into the lumen of the SR 
[228]. As the activity of SERCA2a increases, the amount of Ca
2+
 pumped into the SR also 
Discussion 
 110
increases, resulting in myocardial relaxation and better calcium handling in the 
cardiomyocytes [229]. Improved calcium cycling contributes to a tightly spatiotemporally-
regulated elevated level of intracellular Ca
2+
 ([Ca
2+
]i) and stronger contractions of cardiac 
muscle without increased resting [Ca
2+
]i, which leads to diastolic dysfunction and HF [230].  
PI3K: In this study, inhibition of PI3K with wortmannin resulted in a marked decrease in 
cAMP production and P-PLB(S16). PI3K was described to be important for maintaining 
cAMP production after RLN stimulation [77]. Activation of RXFP1 triggers the activation of 
PI3K, independent of the Gs activation. Activation of PI3K leads to PIP3 production, which 
activates PKC , resulting in activation of AC for further production of cAMP [77, 217, 218]. 
This fact would explain how RXPF1-RLN signaling maintains the amount of cAMP needed 
for downstream signaling activation.  
G: Inhibition of G led to an increase in P-PLB(S16) signal. Kern et al. have described 
that RXFP1 is not easily deactivated and may behave differently than other GPCRs [231]. 
However, the results from the G inhibition could not confirm these finding. G functions 
by recruiting different GRKs to the membrane in order to phosphorylate GPCRs, thereby 
resulting in a desensitization of the receptor [232, 233]. Furthermore, G also plays a role in 
the inhibition of PI3K, which could further decrease GPCRs signal [184, 234, 235]. Thus, it 
is reasonable to assume that RXPF1 might not behave like other GPRCs, when being 
stimulated for a prolonged period of time.  
 Lastly, it should be noted that the RXFP1-RLN pathway was studied in healthy 
cardiomyocytes. It would be interesting to further investigate the RXFP-RLN pathway in 
failing cardiomyocytes. The molecular alterations in these cells could lead to a better 
understanding of the RXFP1-RLN signaling pathway.  
 
6.5 Difference between RXFP1 and -adrenergic signaling 
In this study, RLN is assumed to be a positive inotropic agent when coupled to its 
artificially expressed RXPF1 receptor in the heart. Other positive inotropic agents, such as 
isoproterenol, couple to the naturally expressed -adrenergic receptor (-AR) in the heart to 
produce positive inotropy [236]. Comparing the signaling pathways of both inotropic agents, 
similarity between RLN and ISO can be observed many areas. For example, RLN and ISO 
both signal through Gs and utilize cAMP as a second messenger to activate PKA, which 
leads to an increase in phosphorylation of PLB at Serine 16. However, the strength with 
which RLN and ISO activate the signaling cascade is different.  
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Activation of -AR by isoproterenol stimulates the production of cAMP by AC and 
thereby activates PKA. PKA phosphorylates L-type calcium channels, PLB and RyR2, which 
contributes to the increase of intracellular Ca
2+
 transient, resulting in increased cellular 
contractility [237]. Phosphorylated L-type calcium channels increase the amount of Ca
2+
 
influx into the cell, and phosphorylated RyR2 increases the amount of Ca
2+
 released from the 
SR [168, 170, 229, 238, 239]. Compared to an unstimulated myocardium, this increased 
amount of Ca
2+
 leads to an increase in muscle contraction during the cardiac excitation-
contraction coupling period [237]. During relaxation, phosphorylated PLB increases the 
SERCA2a Ca
2+
 reuptake rate into the SR, leading to better Ca
2+
 cycling and removal of Ca
2+
 
from the cytosol [238-240]. 
In this study, activation of -AR by ISO strongly and abruptly induced phosphorylation 
of PLB at both serine 16 and threonine 17, leading to an enhanced Ca
2+
 cycling within the 
cell. A significant decrease in P-PLB(T17) was detected by a series of blocking experiments, 
after CaMKII activity was chemically blocked in ISO treated cells. In normal excitation-
contraction coupling, PLB phosphorylation at serine 16 is required before threonine 17 can 
be phosphorylated [170]. ISO induces a strong influx of Ca
2+
 into the cytosol from both 
outside of the cell, through L-type calcium channels, and within the cell, from the SR through 
RyR2 [237, 238]. Single site PLB phosphorylation is not sufficient to induce SERCA2a 
activity required for efficient Ca
2+
 reuptake into the SR. As a result, SR Ca
2+
 reuptake rate is 
slower than required, excess cytosolic Ca
2+
 quickly binds to calmodulin to induce the 
activation of CaMKII, which phosphorylates PLB at threonine 17 and thereby further 
increases the activity of SR SERCA2a Ca
2+
 reuptake rate [241]. This chain of 
phosphorylation events happens extremely quickly after -AR stimulation by ISO and 
persisted for hours as PLB phosphorylation status did not return to baseline even 24 hours 
afterward. As a consequence, CaMKII activation from excess cytosolic Ca
2+
 and a prolonged 
phosphorylation of RyR2 and P-PLB(T17) is a hallmark of Ca
2+
 mishandling, which could 
eventually lead to pathological cardiac remodeling and mitochondria dysfunction [242, 243]. 
Hence, CaMKII does play a crucial role in -adrenergic activation compared to RXFP1 
activation. 
In contrast, activation of RXFP1 by RLN induces phosphorylation of PLB at both 
serine 16 and threonine 17 in a more gradual and sequential fashion. Moreover, when 
CaMKII activity was chemically blocked, P-PLB(T17) was unaffected both before and after 
RXFP1 activation by RLN. In addition, Piedras-Renter a et al. discovered that, apart from 
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increased cAMP accumulation, RLN also increases Ca
2+ 
influx through prolonged AP, which 
increases Ca
2+
 current through L-type and T-type calcium channels [62]. Gradually, an 
excess influx of Ca
2+
, which cannot be transferred into the SR by SERCA2a, will bind to 
calmodulin and activate CaMKII, resulting in phosphorylation of PLB at threonine 17 [170]. 
Similar but yet different from -AR signaling, RXFP1 time curve and CaMKII blocking 
experiments presented in this study show that RXFP1-RLN signaling also generated PLB 
phosphorylation at both serine 16 and threonine 17 in the myocardium, but at a much more 
reduced strength. Throughout the experiment, phospholamban phosphorylation at threonine 
17 has never reached a significant level compared to none treated cell. As a result, CaMKII 
activation is much lower in RXFP1 samples treated with RLN and the pathway could be 
conceded as a natural coping mechanism within the cells as previous studies revealed that P-
PLB(S16) is required for P-PLB(T17) sine qua non and a slight CaMKII activation is 
therefore considered as beneficial [236, 244, 245].  
Lastly, this study confirms that RXFP1 activation is independent of -adrenergic 
activation, since blocking of the -adrenergic receptor did not alleviate the downstream 
signaling of RXFP1 stimulation by RLN. In line with previous finding, RXFP1 activation by 
relaxin acts independently of -adrenergic activation [62]. Thus, this evidence strongly 
suggests that RXFP1 has its own independent signaling pathway and – unlike classical -
adrenergic receptor – it is not detrimental to the cells, as it only increases Ca
2+
 influx to the 
level that the cell can physically cope with. 
 
6.6 Similarity between rat, human and mouse RXFP1 signaling 
Many studies have described the similarity between human and rat RXFP1 receptors 
[37, 246]. In this study, the similarity of the receptors was confirmed, as both seem to 
potentially induce positive inotropy when stimulated with recombinant RLN. Human and rat 
RXFP1 are quite similar, sharing approximately 89% similarity in both mRNA and amino 
acid sequence [68, 247-249]. Both also share sequence homology at all ligand biding 
domains [37, 246], suggesting to a belief that both sequences would behave the same way 
when overexpressed and stimulated with recombinant RLN. This assumption was confirmed 
as a combination of human RXFP1 overexpression and RLN stimulation led to an increased 
phosphorylation of PLB at serine 16 at a level similar to what was seen with rat RXFP1 
activation. In addition, the use of human RXFP1 for future gene therapy treatment might be 
more desirable than rat RXFP1 because of a reduced risk for immunological reaction. In 
Discussion 
 113 
conclusion, the human RXFP1 receptor warrants further investigation into its therapeutic 
potential as well.  
 
6.7 Conclusion and outlook 
While the results presented in this study are far from providing a complete 
understanding of the beneficial effects of RXFPI gene therapy and activation by RLN in both 
in vivo and in vitro, they do extend our knowledge of the ectopic expression of RXFP1 and 
its subsequent signaling cascade upon RLN stimulation:  
 A combined treatment consisting of ectopic expression of RXFP1 through RXFP1 
gene therapy and chronic RLN stimulation is capable of rescuing a HF phenotype in an in 
vivo HF model.  
With regard to its mechanism, this study clearly demonstrates that ectopically 
expressed RXFP1 in the left ventricular myocardium has some moderate cardioprotective 
properties, which can blunt the effects of TAC surgery, leading to a reduced pathological 
cardiac molecular remodeling. By combining RXFP1 gene therapy with exogenous 
recombinant RLN administration, these cardioprotective effects are multiplied and a further 
positive inotropic response in the left ventricle is induced. This study also indicates that 
RXFP1 expressed in the ventricle, signals through a Gs subunit of the heterotrimeric G-
protein and PI3K, in order to increase cAMP production, PKA activation, and 
phosphorylation of PLB at serine 16. Lastly, due to similar positive inotropic effects 
observed, both -adrenergic activation and RXFP1 activation were examined. The results 
indicate that induction of RXFP1 leads to mild activation of the downstream signaling 
pathways compared to the induction through -adrenergic receptor. This mild and gradual 
activation might play a key role in preventing RXFP1 from becoming detrimental. 
Still, some questions from this study remain unanswered: 
- Will human RXFP1 exhibit similar behavior compared to rat RXFP1?  
- Will prolonged stimulation of RXFP1 lead to its desensitization? 
- Does RXFP1 remain active after on and off treatment of RLN? 
- What are the long-term consequences of RXFP1 activation by RLN? 
Answering these questions will help us to understand RXFP1-RLN signaling 
transduction in cardiomyocytes further and could lead to the development of a more efficient 
treatment option for HF. Nonetheless, these questions will be addressed in future studies.  
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